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1.	  Introduction	  
1.1.	  Head	  and	  Neck	  Squamous	  Cell	  Carcinoma	  (HNSCC)	  
Head	  and	  neck	  cancers	  are	  the	  six	  most	  malignant	  tumors	   in	  the	  world.	  There	  are	  600,000	  
new	   cases	   diagnosed	   worldwide	   each	   year(1).	   It	   may	   arise	   anywhere	   in	   the	   oral	   cavity,	  
nasopharynx,	  oropharynx,	  hypopharynx	  and	  larynx.	  Tumors	   in	  nasal	  cavities,	  paranasal	  and	  
sinuses	  are	  also	   included	  (Figure	  1).	  Despite	   improvements	   in	  treatment	  strategies	  survival	  
rate	  is	  still	  low	  for	  the	  advanced	  cases;	  the	  5-­‐years	  survival	  at	  early	  stage	  is	  about	  80%	  and	  
drop	   to	   19%	   for	   late	   stage.	   Around	   95%	   of	   head	   and	   neck	   cancers	   are	   squamous	   cell	  
carcinoma	  and	  frequently	  have	  aggressive	  biological	  behavior.	  
Etiology	   of	   head	   and	   neck	   cancers	   is	   multifactorial,	   but	   it	   is	   closely	   linked	   with	   the	  
environmental	   and	   lifestyle	   risk	   factors	   including	   chronic	   tobacco	   smoking	   (strongly	  
associated),	  alcohol	  consumption,	  actinic	  radiation	  and	  inherited	  genomic	  instability.	  Typical	  
HNSCC	  patients	  are	  middle-­‐aged	  with	  a	  history	  of	  chronicle	  use	  of	  alcohol	  and	  tobacco(1).	  	  
	  
	  
Tobacco	  smoking	  and	  alcohol	  consumption–associated	  head	  and	  neck	  cancer	   is	  developing	  
by	  a	  multistep	  progression	  and	  accumulation	  of	  genetic	  and	  epigenetic	  alterations,	  including	  
the	  activation	  of	  oncogenes	  and	  inactivation	  of	  tumor-­‐suppressor	  genes.	  Typical	  alterations	  
in	   genes	   implicated	   in	   HNSCC	   carcinogenesis	   are	   loss	   of	   heterozygosity	   and	  
hypermethylation	  particularly	  at	  chromosomes	  3p,	  9p	  and	  17p,	  resulting	  in	  the	  inactivation	  
of	  p16	  (inhibitor	  of	  cyclin-­‐dependent	  kinase).	  These	  alterations	  are	  typical	  for	  early	  stage	  of	  
carcinogenesis	  found	  in	  dysplasia.	  In	  addition,	  alterations	  at	  the	  chromosomes	  11q,	  4q	  and	  
Figure	  1:	  Head	  and	  neck	  cancer	  localizations.	  	  
Regions	   of	   some	   anatomic	   structures	   that	   are	  
targeted	  in	  HNSCC	  cancer.	  	  
Paranasal	   sinuses,	   nasal	   cavity,	   oral	   cavity,	  
tongue,	   salivary	   glands,	   larynx	   and	   pharynx	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chromosome	  8	  are	  typical	  for	  late	  stage	  carcinogenesis(1,2).	  TP53	  mutations	  are	  present	  in	  
60%-­‐80%	   of	   all	   head	   and	   neck	   cancers.	   Those	   mutations	   are	   hallmarks	   of	   HNSCC	  
carcinogenesis(1,2).	  Others	  mutations	  like	  EGFR	  mutations	  may	  also	  be	  present	  but	  they	  are	  
not	  frequent.	  
The	   prognosis	   for	   patients	   with	   HNSCC	   is	   largely	   determined	   by	   the	   stage	   of	   the	   cancer	  
defined	  as	  “staging”.	  Treatments	  mainly	  depend	  on	  the	   tumor	   localization.	  Tumor	  size	   (T),	  
lymph	   nodes	   extension	   (N),	  metastasis	   (M)	   stages	   are	   additionally	   used	   to	   determine	   the	  
treatment.	  Indeed,	  TNM	  stages	  are	  used	  to	  classify	  different	  groups	  in	  early,	  loco-­‐regionally	  
or	   metastatic	   stages	   to	   determine	   the	   treatment.	   Treatments	   traditionally	   involved	   are	  
chemotherapy,	   radiotherapy	   and	   surgery	   according	   to	   the	   staging(1).	   Other	   additional	  
treatments	   like	   immunotherapy,	  which	   targets	   specific	   pathways	   (i.e.	   cetuximab	   for	   EGFR	  
pathway),	  can	  also	  be	  employed(2).	  
As	  mentioned	  above,	  HNSCC	  is	  strongly	  associated	  with	  chronic	  tobacco	  smoking.	  Between	  
1950	  and	  1960,	  studies	  demonstrated	  the	  evidence	  of	  the	  association	  between	  cigarettes	  -­‐	  
lung	  cancer	  and	  between	  cigarettes	  -­‐	  cardiovascular	  disease.	  Those	  evidences	  were	  proved	  
to	  diminish	  tobacco	  used	  in	  population.	  According	  to	  the	  robust	  correlation	  between	  HNSCC	  
and	   tobacco,	   it	   was	   expected	   the	   incidence	   of	   HNSCC	   to	   decrease	   a	   few	   decades	   after.	  
Indeed,	  statistics	  show	  a	  decrement	  of	  cancers	  localized	  in	  oral	  cavity,	  pharynx	  and	  floor	  of	  
the	   mouth.	   On	   the	   other	   hand,	   incidence	   of	   cancers	   localized	   in	   tongue,	   tonsils	   and	  
oropharynx	  increased	  dramatically(2),	  suggesting	  another	  carcinogens	  exposure	  emerging	  in	  
oncogenesis	  process	  of	  head	  and	  neck	  cancer.	  	  	  
	  
For	  a	  long	  time	  HNSCC	  has	  been	  considered	  like	  one	  monotonous	  disease	  entity,	  but	  recent	  
studies	  highlighted	  a	  subset	  of	  HNSCC	  related	  to	  Human	  Papillomavirus	  (HPV).	  Indeed,	  some	  
studies	  show	  that	  20%	  of	  HNSCC	  are	  HPV	  positive.	  Furthermore,	  HPV	  are	  70%	  causative	  of	  
oropharyngeal	  cancer	  including	  tonsils,	  base	  of	  tongue,	  soft	  palate	  and	  pharyngeal	  wall.	  
It	   is	   clear	   now	   that	   HPV	   affects	   the	   demographical,	   clinical	   and	   histopathological	  
presentation	  of	  the	  HNSCC	  patient	  and	  should	  be	  considered	  as	  a	  unique	  clinical	  entity.	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1.2.	  Head	  and	  neck	  cancer	  associated	  with	  Human	  Papilloma	  Virus	  (HPV)	  
HPV	   is	   a	   sexually	   transmitted	   virus,	   especially	   known	   for	   its	   great	   implication	   in	   cervix	  
carcinoma	   amongst	   female	   population.	   It	   is	   also	   responsible	   for	   penile	   cancer	   and	   rectal	  
cancer	  more	   prevalent	   amongst	  male	   population.	   HPV	   is	   recently	   known	   to	   have	   also	   an	  
implication	   in	  HNSCC.	   Indeed,	  HPV	  plays	  a	  role	   in	  the	  pathogenesis	  of	  a	  subset	   from	  these	  
cancers,	  particularly	   in	   those	   that	  arise	   in	   the	  area	  of	  oropharynx	   (OPC)	  and	   in	   the	   lingual	  
and	  palatine	  tonsils(3).	  
The	  etiology	  of	  HNSCC	  linked	  to	  HPV	  infection	  is	  predominantly	  sexually	  transmitted.	  In	  fact,	  
the	   major	   risk	   factors	   for	   HPV-­‐positive	   HNSCC	   are	   certain	   sexual	   behaviors,	   such	   as	   high	  
number	  of	  sexual	  partners,	  history	  of	  performing	  oral	  sex	  and	  oral-­‐anal	  sex,	  history	  of	  genital	  
warts,	   and	   infrequent	   use	   of	   condoms.	   Other	   factors	   are	   more	   linked	   with	   the	   immune	  
system	  status,	   including	  aging,	  history	  of	  sexual	  transmitted	  disease,	  HIV	  infection,	  severity	  
in	  immunosuppression	  (transplant	  patients),	  and	  Fanconia	  anemia	  (genetic	  susceptibility)(3–
5).	  	  
In	  most	  cases,	  HPV-­‐positive	  oropharyngeal	  cancer	  (OPC)	  is	  associated	  with	  high-­‐risk	  HPV	  16	  
subtype.	  Indeed,	  high-­‐risk	  HPV	  16	  according	  to	  some	  studies	  seems	  to	  be	  causally	  implicated	  
in	  about	  90-­‐95%	  of	  HPV-­‐positive	  HNSCC	  tumors(3,4).	  Other	  subtypes	  including	  HPV	  18,	  -­‐31,	  -­‐
33,	  -­‐45	  and	  -­‐53	  are	  also	  important	  etiological	  agents.	  
Prevalence	   of	   HPV	   varies	   widely	   depending	   on	   geographical	   location	   and	   on	   sexual	  
behaviors.	   In	   2009,	   prevalence	  of	  HPV	   type	  16	   genital	   infections	   in	   the	  United	   States	  was	  
about	  27%	  amongst	  women	  and	  about	  60%	  amongst	  men	  (both	  gender	  aged	  14	  to	  59	  years).	  	  
As	   mentioned	   before,	   the	   prevalence	   of	   classical	   HNSCC	   (associated	   with	   risk	   factors	  
including	  tobacco	  and	  alcohol)	  is	  decreasing	  whereas	  the	  prevalence	  of	  HNSCC	  linked	  to	  HPV	  
was	  constantly	  increasing	  last	  decade	  and	  continues	  to	  increase	  nowadays	  (5).	  	  
Another	   study	   in	   2002	   estimated	   that	   about	   5%	   of	   worldwide	   new	   cancer	   cases	   were	  
attribute	  to	  HPV,	  making	  HPV	  one	  of	  the	  most	  important	  infectious	  causes	  of	  cancers	  (6).	  
HPV	   totally	   changed	   the	   face	   of	  HNSCC	   traditionally	   associated	  with	   tobacco	   use.	   Indeed,	  
patients	  HPV-­‐positive	  HNSCC	  tend	  to	  be	  younger	  (4).	  Moreover,	  HPV	  status	  seems	  to	  be	  an	  
important	   prognosis	   factor.	   Previous	   studies	   show	   that	   HPV	   status	   is	   associated	   with	  
favorable	   outcomes,	   better	   overall	   survival,	   disease-­‐free	   survival	   and	   lower	   recurrence	  
rates(5).	  It	  has	  also	  been	  demonstrated	  that	  this	  status	  has	  better	  response	  to	  treatments,	  in	  
particularly	  with	  induction	  chemotherapy,	  radiotherapy	  and	  chemoradiotherapy	  (7).	  Patients	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with	  HPV-­‐positive	   status	   in	   HNSCC	   present	   less	   exposure	   to	   tobacco	   and	   chronicle	   use	   of	  
alcohol.	   This	   lack	   of	   exposure	   could	   be	   one	   explanation	   among	   others	   of	   the	   better	  
prognosis.	  
	  
1.3.	  Human	  Papilloma	  Virus	  16	  (HPV	  16)	  
HPV	  is	  a	  small	  circular	  double-­‐stranded	  DNA	  virus	  of	  approximately	  8000	  base	  pairs,	  and	  has	  
a	   specific	   tropism	   for	   squamous	   cell	   epithelia	   (basal	   keratinocytes)(8).	   More	   than	   120	  
different	  types	  of	  HPV	  have	  been	  identified	  and	  separated	  in	  two	  groups	  according	  to	  their	  
tissue	  tropism	  and	  their	  carcinogenesis	  ability:	  low-­‐risk	  and	  high-­‐risk.	  Low-­‐risk	  HPV	  (e.g.	  HPV-­‐
6,	   -­‐11)	   are	   cutaneous	   types	   found	   in	   benign	   genital	   warts	   and	   in	   other	   non-­‐malignant	  
lesions.	   In	   contrary,	   high-­‐risk	   HPV	   (e.g.	   HPV-­‐16,	   -­‐18)	   are	   mucosal	   types	   found	   in	  
precancerous	  and	  cancerous	  lesions.	  	  
	  
High	   risk	  HPV16	   is	   the	  most	   virulent	   and	   aggressive	  HPVs	   and	   is	   the	  main	   cause	  of	   cervix	  
cancer	  and	  of	  a	  subset	  of	  HNSCC.	   Its	  genome	  consists	  of:	  non-­‐coding	  region,	  6	  early	  genes	  
(E1-­‐7)	   and	   2	   late	   genes	   (L1-­‐2).	   Other	   regions	   such	   as	   long	   control	   region	   (LCR)	   are	   also	  
present	  in	  the	  genome’s	  virus,	  which	  are	  important	  for	  the	  production	  of	  the	  virus	  (8)	  (Figure	  
2).	  
	  
E6	  and	  E7	  are	   two	  oncogenes	   that	  are	   the	  onset	  of	  HPV	  mediated	  carcinogenesis(9).	  They	  
block	   some	   important	   tumor	   suppressors	   and	   activate	   oncogenes	   that	   lead	   to	   cell	   cycle	  
	  	  
Figure	  2:	  HPV	  16	  model.	  	  
1)	  Early	  region	  (E1-­‐7)	  codes	  for	  non-­‐structural	  genes	  
(cellular	  transformation).	  
	  
2)	   Late	   region	   (L)	   codes	   for	   two	   structural	   proteins	  
L1	  and	  L2	  that	  form	  the	  capsid.	  
	  
3)	   Long	   Control	   Region	   (LCR),	   a	   non-­‐coding	   region	  
that	  regulates	  replication	  and	  gene	  functions.	  
	  
Oncoproteins	   E6	   and	   E7	   are	   required	   for	   tumor	  
maintenance.	  
E6	   inhibits	  p53	  (stop	  apoptosis),	  E7	   inhibits	  Rb	   (cell	  
growth	  arrest).	  
	  




	   	   	   	   	   	   	  	  
	   	   	   8	  
deregulation	   and	   cell	   immortalization.	   The	   loss	   of	   this	   regulation	   leads	   to	   neoplasia.	  
Accumulation	  of	   others	   genetic	   damages	  will	   ultimately	   lead	   to	  malignant	   transformation.	  
All	  these	  steps	  will	  be	  described	  in	  the	  next	  paragraph.	  
	  
1.4.	  Invasion	  and	  carcinogenesis	  of	  high-­‐risk	  HPV	  
HPV	   associated	   cancer	   in	   oropharynx	   might	   share	   many	   features	   with	   carcinogenesis	   in	  
cervical	  cancer	  amongst	  women.	  
Carcinogenesis	  of	  HPV	  16	  begins	  with	  basal	  cell	  infection	  of	  the	  epithelium.	  This	  infection	  is	  
happening	  only	  when	   there	   is	   abrasion	   (micro	  wounds)	   in	   the	  epithelia.	   The	  virus	   reaches	  
the	  basal	  layer	  of	  the	  epithelia	  and	  infects	  some	  basal	  cells	  (Figure	  3)(10).	  HPV16	  depends	  on	  
the	   host	   cell	   replication	  machinery	   to	   copy	   its	   own	   DNA.	   To	   integrate	   DNA	   host	   cell	   the	  
necessary	  proteins	  are	  only	  produced	  during	  the	  mitosis	  (actively	  dividing	  cell)(11).	  	  
	  
	  
Previously,	   studies	   have	   shown	   that	   mitosis	   phase	   progression	   is	   required	   for	   early	   gene	  
expression	  of	  HPV.	  Resulting	  population	  of	  host	  cells	  with	  the	  integrated	  HPV	  DNA	  into	  their	  
genomes	   will	   accumulate	   genetic	   damages	   and	   alterations.	   These	   transformations	   in	   the	  
important	   cell	   cycle	   pathways	   can	   ultimately	   lead	   to	   malignant	   transformation	   and	   to	  
carcinoma(11).	  
Cellular	  transformation	  and	  maintenance	  of	  malignant	  phenotype	   is	  accomplished	  by	  high-­‐
risk	  HPV	  16	  oncoproteins	  (E6	  and	  E7).	  There	  are	  other	  oncoproteins,	  which	  can	  play	  a	  role	  in	  
the	  carcinogenesis	  of	  HPV,	  but	  they	  will	  not	  be	  discussed	  in	  this	  study(12).	  	  
Figure	  3:	  Natural	  way	  of	  HPV	  infection	  
	  
HPV	   infects	   keratinocytes	   in	   the	   basal	   layer	   that	  
are	  exposed	  by	  microwounds.	  
Differentiation	   of	   HPV	   cells	   induces	   the	  
productive	   phase	   of	   the	   viral	   life	   cycle,	   which	  
requires	   cellular	  DNA	  synthesis	  machinery	  of	   the	  
host	  cell.	  The	  expression	  of	  E6	  and	  E7	  deregulates	  
cell	   cycle	   control	   that	   pushes	   the	   cell	   in	   the	   S	  




Picture	   from	   NATURE	   REVIEW	   CANCER,	   Human	  
papilloma	   oncoproteins:	   pathway	   to	   transformation,	   C	  
Moody	  et	  All.	  
	   	   	   	   	   	   	  	  
	   	   	   9	  
The	  carcinogenesis	  and	  the	  maintenance	  of	  malignancy	  are	  driven	  by	  the	  E6	  and	  E7	  proteins	  
and	  it	  is	  shown	  in	  the	  Figure	  4.	  
	  
Figure	  4:	   carcinogenesis	  of	  E6	  and	  E7,	  picture	  taken	  from	  Clinical	  Cancer	  Research,	  Human	  Papilloma	  Virus	  in	  Head	  and	  Neck	  Cancer:	   its	  
Role	  in	  Pathogenesis	  and	  Clinical	  	  	  Implications,	  H.	  Chung	  et	  all,	  2009.	  	  
E6	   is	  required	  to	  deregulate	  both	  G1/S	  and	  G2/M	  cell	  cycle	  checkpoint	  by	   interaction	  with	  
E6-­‐associated	   protein	   (E6-­‐AP)	   and	   targeting	   of	   p53	   tumor	   suppressor	   protein	   for	  
ubiquitination,	   which	   results	   in	   rapid	   degradation	   of	   p53.	   Inactivation	   of	   p53	   results	   in	  
apoptosis	   resistance	  and	  accumulation	  of	  DNA	  damages	  which	   lead	   to	  genomic	   instability.	  
The	   protein	   complex	   E6/E6-­‐AP	   plays	   also	   a	   role	   in	   cellular	   immortalization	   by	   degrading	  
NFX1	  that	  is	  a	  transcriptional	  repressor	  of	  hTERT	  that	  results	  in	  its	  activation	  and	  in	  cellular	  
immortalization	  by	  inhibiting	  telomerase	  erosion(12,13).	  
E7	  is	  required	  to	  deregulate	  G1/S	  phase	  of	  the	  cell	  cycle	  by	  binding	  cullin	  2	  ubiquitin	  ligase	  
which	  ubiquitinates	  the	  retinoblastoma	  (pRb)	  tumor	  suppressor	  protein.	  The	  absence	  of	  pRb	  
function	   leads	   to	   cell	   proliferation	   because	   E2F	   family	   of	   transcription	   factors	   can	   induce	  
transcription	  of	   the	  S	  phase	  genes	  when	  pRb	   is	  not	   functional.	   In	  addition,	  p16	   is	  a	  cyclin-­‐
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dependent	   kinase	   inhibitor	   whose	   expression	   increases	   in	   response	   to	   Rb	  
inactivation(12,14).	  Therefore	  the	  expression	  status	  of	  p16	  is	  strongly	  correlated	  with	  tumor	  
HPV	   status(5,15).	   So	   it	   is	   commonly	   used	   as	   a	   surrogate	   marker	   in	   HPV-­‐positive	   tumors	  
detection.	   Indeed,	  most	  of	   tumors	   (96%)	   that	  are	  positive	   for	  HPV	  by	   In	  Situ	  Hybridization	  
are	  also	  positive	  for	  p16	  Immunohistochemistry(4,15).	  It	   is	  now	  well	  known	  that	  E6	  and	  E7	  
are	   required	   for	   tumor	   maintenance	   in	   oropharyngeal	   cancer	   as	   in	   the	   cervix	   cancer,	  
because	  studies	  have	  demonstrated	  when	  E6	  and	  E7	  are	  inhibited	  in	  a	  tumor	  cell	  it	  induces	  
apoptosis	  and	  decrease	  cell	  viability(16).	  	  	  
The	   process	   of	   transforming	   normal	   cell	   into	   cancerous	   ones	   is	   very	   slow;	   therefore	  HPV-­‐
induced	  tumors	  may	  occur	  in	  people	  that	  have	  been	  infected	  with	  HPV	  for	  a	  long	  time	  ago	  
(10-­‐15	  years).	  It	  is	  important	  to	  notice	  that	  majority	  of	  individuals	  infected	  will	  not	  develop	  
cancer,	  because	  most	  of	  the	  infections	  are	  rapidly	  cleared	  by	  the	  immune	  system	  and	  do	  not	  
progress	  to	  carcinoma.	   In	  all	  steps	  of	  the	  carcinogenic	  process	  there	   is	  a	  possibility	   for	  the	  
immune	  system	  to	  clear	  HPV	  and	  stops	  the	  progression	  to	  carcinoma(11,16).	  
	  
1.5.	   Prognosis	   and	   response	   to	   treatment	   of	   HPV-­‐positive	   oropharyngeal	   cancer	  
(OPC)	  
Patients	  with	  HPV-­‐positive	  OPC	  tend	  to	  be	  younger	  by	  5-­‐10	  years	  and	  are	  more	  likely	  to	  be	  
non-­‐smokers	  and	  non-­‐drinkers	  compared	  to	  HPV-­‐negative	  OPC	  patients.	  
There	  is	  evidence	  that	  HPV	  is	  an	  important	  prognosis	  factor	  associated	  with	  better	  outcomes	  
and	   survival	   compared	   to	  patients	  with	  HNSCC	  HPV-­‐negative	   tumors.	   In	   fact	   retrospective	  
studies	  demonstrated	  a	  50-­‐80%	  reduction	  risk	  of	  cancer	  related	  death	  for	  HPV-­‐positive	  than	  
HPV-­‐negative	   tumors.	  Many	   others	   studies	   have	   shown	   that	   after	   adjustment	   of	   age	   and	  
tumor	   stages,	   HPV-­‐positive	   tumors	   are	   associated	   with	   better	   overall	   survival,	   local	  
recurrences	  free	  survival,	  disease-­‐free	  survival	  and	  better	  response	  to	  treatment	  (7).	  
Improved	  prognosis	  and	  response	  to	  therapy	  in	  HPV-­‐positive	  tumors	  may	  be	  associated	  with	  
the	   absence	   of	   TP53	   mutations.	   In	   HPV	   transformed	   cells	   p53	   and	   Rb	   tumor	   suppressor	  
genes	  are	  wild	  type,	  meaning	  that	  the	  pathways	  are	  present	  and	  intact	  but	  dormant	  due	  to	  
the	  expression	  of	  E6	  and	  E7	  proteins.	  In	  the	  absence	  of	  mutations,	  the	  apoptotic	  pathways	  
still	  functional	  and	  can	  be	  partially	  reactivated	  in	  response	  to	  radiation	  treatment	  compared	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with	   the	   HNSCC	   HPV-­‐negative	   tumors	   in	   which	   mutations	   are	   limiting	   the	   response	   to	  
therapy.	  	  
	  
Smocking	  seems	  to	  affect	  the	  survival	  of	  patients	  with	  HPV-­‐positive	  OPC	  in	  a	  negative	  way.	  
Studies	  demonstrated	  that	  overall	  survival	  and	  recurrences	  were	  better	  in	  HPV-­‐positive	  OPC	  
non-­‐smokers	   that	   in	   HPV-­‐positive	   OPC	   smokers.	   As	   consequence,	   tobacco	   has	   negative	  
influences	   even	   in	   patients	   with	   HPV-­‐positive	   tumor.	   We	   could	   explain	   these	   negative	  
influences	  by	  the	  fact	  that	  smoking	  may	  contribute	  to	  increase	  in	  EGFR	  expression	  (17).	  
	  
1.6.	  HPV	  Vaccine	  
Some	  vaccines	  are	  available	  on	  the	  market	  and	  are	  a	  possible	   intervention	  to	   fight	  against	  
HPV,	  in	  particularly	  Gardasil®	  that	  targets	  most	  prevalent	  HPV-­‐6,	  -­‐11,	  -­‐16,	  and	  -­‐18	  subtypes.	  
This	   vaccine	   has	   been	   demonstrated	   to	   be	   highly	   effective	   in	   preventing	   cervix	   cancer	  
amongst	   female.	   If	   it	   is	   successful	  by	   reducing	   the	  prevalence	  of	  HPV16,	  we	  would	  expect	  
that	   it	   will	   also	   reduce	   the	   prevalence	   of	   OPC	   HPV-­‐positive	   tumors,	   but	   it	   remains	   to	   be	  
determined.	   This	   expectation	   can	  be	  used	   as	   an	   argument	   to	   extend	   vaccination	  program	  
and	   include	   boys	   for	   the	   future	   (18).	   However,	   prophylactic	   HPV	   vaccines	   will	   eventually	  
reduce	   infections	  by	   the	  most	  prevalent	  high-­‐risk	  HPV	   subtypes,	  but	  do	  not	   cover	   all	   high	  
risks	  HPVs.	  Furthermore,	  this	  vaccine	  has	  demonstrated	  to	  have	  a	  lack	  of	  therapeutic	  action,	  
meaning	   that	   it	  will	   not	   affect	   the	   already	   existing	  HPV	   infections.	   Those	   infections	   could	  
lead	  to	  a	  probable	  cancer	  in	  a	  decade	  or	  more.	  Taking	  that	  into	  consideration,	  it	  encourages	  
to	  broaden	  an	  interest	  of	  research	  for	  HPV	  tumors.	  
	  
1.7.	  Aim	  of	  the	  study	  
HPV-­‐positive	   HNSCC	   demonstrated	   to	   have	   completely	   different	   clinical,	   histological	   and	  
molecular	  features	  and	  also	  showed	  to	  have	  a	  better	  prognostic	  and	  response	  to	  treatment	  
than	  the	  HPV-­‐negative	  HNSCC.	  	  
However,	  patients	  with	  HPV-­‐positive	  tumors	  continue	  to	  be	  treated	  exactly	  the	  same	  way	  as	  
the	  HPV-­‐negative	  patient	  (19).	  A	  standardization	  of	  assay	  methodology	  is	  required	  to	  reliably	  
detect	  HPV-­‐positive	  tumor	  either	  by	  a	  direct	  detection	  of	  virus	  related	  molecules	  (DNA,	  RNA	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and	   proteins)	   or	   detection	   of	   the	   specific	   molecular	   markers	   related	   to	   the	   HPV-­‐induced	  
tumorigenesis.	  It	  has	  to	  be	  sensitive,	  cost	  effective	  and	  easy	  to	  use	  in	  laboratories	  (20).	  
The	   aim	   of	   this	   study	   is	   first	   to	   test	   some	   biopsy	   samples	   to	   detect	   HPV	   in	   tumor,	   and	  
secondly	  to	  measure	  expression	  of	  genes	  related	  to	  the	  HPV-­‐induced	  tumorigenesis	  in	  order	  
to	  find	  a	  possible	  marker	  (21,22).	  	  	  
2.	  	   MATERIALS	  AND	  METHODS	  
2.1.	  	   Materials	  
2.1.1.	  	  Reagents	  
PCR	  reaction	  mixture:	  
12.5	  µl	  of	  Go	  Taq	  DNA	  polymerase	  	  	  
0.6	  µl	  of	  Forward	  and	  Reverse	  primers	  
2	  µl	  of	  template	  (cDNA)	  
Adjusted	  to	  25	  µl	  with	  ddH20	  
	  
2.1.2.	  	  Equipment	  
-­‐Plastic	  vessels	  (VWR	  International	  GMBH)	  
-­‐Biometra	  TProfessional	  Basic	  Thermal	  Cycler	  
-­‐	  Thin-­‐walled	  and	  flat-­‐capped	  tube	  (Chemie	  Brunschwig	  AG)	  
-­‐Go	  Taq	  DNA	  polymerase	  master	  mix	  (Promega;	  contains	  GoTaq®	  DNA	  Polymerase,	  5X	  Green	  
GoTaq®	  Reaction	  Buffer	  and	  5X	  Colorless	  GoTaq®	  Reaction	  Buffer)	  
-­‐Agarose	  gels	  (Chemie	  Brunschwig	  AG)	  
-­‐Material	  for	  PCR:	  combs	  (BioRad)	  
-­‐	  Inverted	  Zeiss	  microscope	  
-­‐Zymo	  kit	  and	  Direct-­‐ZOL	  RNA	  Mini-­‐Prep	  (Zymoresearch)	  
-­‐BCA	  protein	  assay	  kit	  (Pierce	  #	  23227)	  
-­‐Blotek	  Epoch	  system	  
-­‐Gens	  1.10	  Software	  
-­‐	  ClustalW	  software	  
-­‐	  Clone	  Manager	  Professional	  software	  (Version	  9	  for	  Windows,	  http://www.scied.com)	  
-­‐Mini-­‐Protean	  II	  dual	  slab	  cells	  (Bio-­‐Rad)	  
qRT-­‐PCR	  reaction	  mixture:	  
5	  µl	  of	  Fast	  SYBR	  Green	  Master	  mix	  2x	  
0.2	   µl	   of	   Forward	   and	   Reverse	   primers	   10µM	  
stock	  
2	  µl	  of	  template	  (cDNA)	  
Adjusted	  to	  10	  µl	  with	  dd	  H20	  
	   	   	   	   	   	   	  	  
	   	   	   13	  
-­‐Mini	  Protean	  II	  transfer	  system	  (Biorad)	  
-­‐Nitrocellulose	  sheet	  (Protran	  BA-­‐85,	  0.45	  μm)	  






-­‐	  Nanodrop	  spechtrophotometry	  (test	  type:	  nucleic	  acid)	  
-­‐RX	  detection	  box	  
-­‐	  X-­‐ray	  film	  (Fuji)	  
	  
2.1.3.	   Buffers	  and	  solutions	  
10x	  running	  buffer	  (SDS-­‐PAGE)	  
Trizma	  base:	  30.3	  g	  
Glycine:	  144	  g	  
20%	  SDS:	  50	  ML	  
Add	  H2O	  to	  reach	  1	  litter	  
	  
KLB-­‐Buffer	  
25	  mM	  Tris-­‐HCl	  (pH	  7.4)	  
150	  mM	  NaCl,	  
5	  mM	  EDTA	  
10%	  glycerol,	  	  
1%	  Triton	  X-­‐100,	  	  
10	  mM	  sodium	  pyrophosphate,	  
10	  mM	  beta-­‐glycerol	  phosphate,	  	  
1	  mM	  sodium	  orthovanadate,	  
1	  mM	  DTT,	  	  
1	  mM	  PMSF,	  
0.02	  mg/ml	  aprotinin,	  	  
10x	  transfer	  buffer	  (western	  blotting)	  
Trizma	  base:	  30.3	  g	  
Glycine:	  144	  g	  
10%	  Ethanol	  or	  20%	  methanol	  for	  small	  proteins	  
Add	  H2O	  to	  reach	  1	  litter	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10	  mM	  sodium	  fluoride	  	  
0.1	  mM	  sodium	  pervanadate	  
	  
2.1.4.	   Cell	  lines	  and	  antibodies	  
Cell	  lines	   Localization	   HPV	  Status	   P53	  Status	  
SCC-­‐090	   Oral	  cavity	   HPV	  16	  positive	   Wild-­‐type	  p53	  
LAU	  2068	   Oral	  cavity	   -­‐	   Mutant	  p53	  
LAU	  2106	   Oral	  cavity	   -­‐	   Mutant	  p53	  
LAU	  2092	   Oropharynx	   -­‐	   Wild-­‐type	  p53	  
LAU	  2089	   Oral	  cavity	   -­‐	   Wild-­‐type	  p53	  
	  
Tumour	  samples	   Localization	   HPV	  Status	  
25	   Oral	  cavity	   HPV	  33	  positive	  
27	   Oral	  cavity	   HPV	  negative	  
	  
Antibodies	   Species	   Dilution	  
SHISA2	   Rabbit	  polyclonal	   1:2500	  
	  
2.2.	   Methods	  
2.2.1.	   Tissue	  samples	  
RNA	  from	  40	  biopsies	  was	   from	  the	  University	  Hospital	  of	   the	  canton	  de	  Vaud	   (CHUV).	  All	  
tissue	  samples	  were	  collected	  during	   the	  surgery	  and	  before	   the	   initiation	  of	  any	  previous	  
treatment	  (chemotherapy	  or	  radiotherapy).	  The	  biopsies	  were	  coming	  from	  oral	  cavity	  and	  
oropharynx.	  All	   samples	  were	   collected	  with	  patient	   consent	  under	   approval	   of	   the	  ethics	  
commission	  of	  the	  institution	  (protocol	  89/08).	  	  
Cell	  lines	  
Human	  SCC-­‐090	  cell	  line	  (HPV16-­‐positive)	  was	  purchased	  from	  DSMZ	  (Germany);	  Hela	  (ATCC	  CCL-­‐2™)	  cell	  line	  was	  purchased	  from	  ATCC,	  TC-­‐1	  cell	  line	  was	  kindly	  provided	  by	  Dr.	  Denise	  
Nardelli	   Haefliger	   (CHUV).	   LAU-­‐2068,	   LAU-­‐2081,	   LAU-­‐2089,	   LAU-­‐2092,	   and	   LAU-­‐2106	   cell	  
lines	  were	  established	  by	  Dr.	  Jean-­‐Paul	  Rivals	  (CHUV)	  from	  head	  and	  neck	  cancer	  samples.	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Cell	  culture	  methods	  
The	  preparation	  of	  media	  and	  all	  cell	  culture	  work	  were	  performed	  in	  a	  laminar	  flow	  hood,	  
using	   standard	   techniques	   (Freshney,	   1987).	   Cells	   were	   grown	   in	   a	   CO2	   incubator	   in	   an	  
atmosphere	   containing	   5%	   CO2	   either	   attached	   to	   plastic	   (anchorage-­‐dependent)	   or	   in	  
suspension	   in	   sterile,	   disposable	   plastic	   vessels	   (VWR	   International	   GMBH).	   Diluting	   the	  
cultures	   with	   fresh	   medium	   every	   2-­‐3	   days	   carried	   out	   feeding	   and	   subculturing	   of	  
suspension	  cells.	  Passage	  of	  adherent	  cells	  was	  performed	  every	  3-­‐10	  days,	  when	  they	  had	  
reached	  confluency.	  Most	  cell	  lines	  reached	  confluence	  after	  3-­‐4	  days,	  however,	  SCC-­‐090	  cell	  
line	  grow	  slow	  reaching	  confluence	  after	  around	  10	  days.	  The	  cells	  were	  then	  detached	  from	  
the	   dish	   with	   trypsin,	   terminating	   the	   proteolysis	   reaction	   with	   FCS.	   We	   checked	   the	  
detachment	   of	   the	   cells	   with	   an	   inverted	   Zeiss	   microscope.	   The	   cells	   were	   collected	   by	  
centrifugation	   (400xg,	   5	   min,	   at	   room	   temperature)	   and	   plated	   in	   fresh	   medium.	   When	  
extracts	  had	   to	  be	  prepared,	   the	  cells	  were	  mechanically	   scraped	  off	   from	  the	  substratum	  
with	  a	  rubber	  policeman	  in	  a	  lysis	  buffer.	  
Viable	  cell	  count	  
A	  small	  sample	  (0.1	  ml)	  of	  suspension	  culture	  was	  mixed	  with	  the	  same	  volume	  of	  a	  solution	  
prepared	   from	  4	  parts	   of	   a	   0.2%	   (w/v)	   Trypan	  blue	   stock	   solution	   and	   1	   part	   of	   5X	   saline	  
(4.25%	  NaCl	   in	  dist.	  H2O).	  The	   total	  number	  of	   cells	  and	   the	  number	  of	   stained	  cells	  were	  
counted	   in	   a	   hemocytometer.	   Cell	   viability	   was	   calculated	   as	   the	   ratio	   between	   the	   total	  
number	  of	  cells	  and	  the	  number	  of	  stained,	  dead	  cells.	  
Freezing	  of	  cells	  
The	  cells	  were	  pelleted	  by	  centrifugation	  at	  400xg	  for	  5	  min,	  the	  supernatant	  was	  aspirated,	  
and	  the	  cell	  pellet	  was	  re-­‐suspended	  at	  room	  temperature	  in	  1	  ml	  of	  freezing	  solution	  (20%	  
FCS	   +	   10%	   DMSO	   in	   RPMI-­‐1640)	   in	   a	   cryovial	   (Nunc).	   The	   vials	   were	   transferred	   to	   a	  
styrofoam	   freezing	   box	   and	   kept	   overnight	   at	   –85°C.	   On	   the	   next	   day,	   the	   vials	   were	  
transferred	  to	  a	  liquid	  nitrogen	  tank.	  
Thawing	  of	  cells	  
After	  removal	  from	  the	  liquid	  nitrogen	  tank,	  the	  frozen	  cell	  suspension	  was	  quickly	  thawed	  
in	  a	  37°C	  water	  bath	  (about	  1	  min).	  The	  suspension	  was	  diluted	  in	  a	  15-­‐ml	  Falcon	  centrifuge	  
tube	  with	  5	  ml	  of	  warm	  growth	  medium	  (37°C)	  and	  centrifuged	  at	  400xg	  for	  5	  min.	  After	  the	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supernatant	  was	  aspirated,	  the	  cells	  were	  re-­‐suspended	  in	  10ml	  of	  medium	  and	  transferred	  
in	  a	  culture	  flask.	  
	  
2.2.2.	  DNA	  methods	  
2.2.2.1.	   	  Primer	  design	  
Nucleotide	  sequences	  of	   the	   full	  genomes	  of	  HPV16	   (104	  genomes),	  HPV18	   (24	  genomes),	  
HPV33	   (22	   genomes),	   and	  HPV56	   (6	   genomes)	   subtypes	  were	   downloaded	   from	   the	  NCBI	  
nucleotide	   database.	   Sequences	   were	   aligned	   using	   the	   ClustalW	   software	   in	   order	   to	  
identify	  regions	  of	  the	  HPV	  genomes	  suitable	  for	  design	  of	  the	  subtype-­‐specific	  primers.	  This	  
analysis	  revealed	  that	  the	  best	  region	  for	  placing	  of	  primers	  is	  the	  end	  and	  begin	  of	  the	  E6	  
and	   E7	   open	   reading	   frames	   (ORFs),	   respectively,	   because	   significant,	   subtype-­‐related	  
diversification	  of	  the	  nucleotide	  sequences	  has	  been	  noticed	  in	  this	  genomic	  region.	  Design	  
of	  primer	  pairs	  was	  performed	  using	  the	  Clone	  Manager	  Professional	  software	  (Version	  9	  for	  
Windows,	   http://www.scied.com).	   In	   order	   to	   be	   able	   to	   detect	   simultaneously	   HPV	  
subtypes	   in	   the	   clinical	   samples	   by	   a	   standard	   PCR	   followed	   by	   an	   analytical	   agarose	   gel	  
electrophoresis,	  subtype-­‐specific	  primers	  were	  designed	  to	  amplify	  PCR	  products	  of	  different	  
length:	  109	  bp	  (HPV16),	  84	  bp	  (HPV18),	  173	  bp	  (HPV33),	  and	  136	  bp	  (HPV56).	  	  	  
Gene-­‐specific	   primers	   were	   either	   selected	   from	   Primer	   Bank	  
(http://pga.mgh.harvard.edu/primerbank/index.html)	   and	   RTPrimerDB	   databases	  
(http://medgen.ugent.be/rtprimerdb/index.php)	   or	   designed	   using	   the	   Clone	   Manager	  
Professional	  software.	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2.2.2.2.	   	  Polymerase	  Chain	  Reaction	  (PCR)	  
Polymerase	  Chain	  Reaction	  
Polymerase	   chain	   reaction	   (PCR)	   was	   performed	   on	   the	   8	   (5	   samples)	   pools	   of	   40	   cDNA	  
samples	  from	  the	  biopsies	  and	  on	  cDNA	  from	  the	  head	  and	  neck	  cancer	  cell	  lines	  in	  order	  to	  
detect	   the	   presence	   of	   the	   expressed	  HPV	   transcripts.	   PCR	  was	   also	   performed	   using	   the	  
HPV-­‐positive	  cell	  lines	  as	  a	  positive	  control.	  	  
DNA	   amplification	   via	   the	   polymerase	   chain	   reaction	   was	   performed	   in	   the	   Biometra	  
TProfessional	  Basic	  Thermal	  Cycler.	  We	  used	  the	  following	  reagents	  in	  a	  0.2	  ml	  thin-­‐walled,	  
flat-­‐capped	  tube	  (Chemie	  Brunschwig	  AG)):	  2	  µl	  of	  template	  DNA	  (cDNA),	  0.6	  µl	  of	  forward	  
and	   reverse	   primers	   targeting	   the	   region	   to	   be	   amplified,	   and	   Go	   Taq	   DNA	   polymerase	  
master	  mix	  (Promega;	  contains	  GoTaq®	  DNA	  Polymerase,	  5X	  Green	  GoTaq®	  Reaction	  Buffer	  
and	   5X	   Colorless	   GoTaq®	   Reaction	   Buffer).	   The	   cycling	   protocol	   consisted	   of	   an	   initial	  
denaturation	   at	   95°C	   during	   120	   seconds	   and	   30	   cycles	   under	   the	   following	   conditions:	  
denaturation	  at	  94°C	  for	  30	  sec,	  annealing	  of	  the	  primers	  at	  55°C	  for	  30	  sec,	  and	  extension	  of	  
the	   primers	   at	   72°	   C	   for	   30	   seconds,	   and	   the	   last	   step	   is	   final	   extension	   at	   72°C	   for	   400	  
seconds.	   After	   PCR	   amplification,	   aliquots	   of	   the	  mixture	  were	   loaded	   onto	   1.5%	   agarose	  
gels	  (Chemie	  Brunschwig	  AG)	  and	  electrophoresed	  as	  described	  below.	  To	  prepare	  samples	  
for	  electrophoresis,	  1	  µl	  of	  SYBR	  Safe	  DNA	  Gel	  Stain	  loading	  buffer	  was	  added	  to	  every	  25	  µl	  
of	  DNA	  solution.	  The	  amplification	  products	  were	  visualized	  with	  a	  mixture	  of	  Dye	  Blue,	  and	  
their	  size	  was	  estimated	  using	  100bp	  DNA	  Ladder	  (6	  µl	  per	  lane).	  
Agarose	  gel	  electrophoresis	  
Agarose	   gel	   1.5%	   was	   prepared	   by	   heating	   a	   quantity	   of	   solution	   (in	   order	   to	   have	   a	  
thickness	  of	  5-­‐10mm)	  in	  a	  microwave	  oven.	  Before	  pouring	  the	  gels,	  we	  needed	  to	  wait	  few	  
minutes	  for	  the	  solution	  to	  cool	  to	  around	  50°C.	  The	  gel	  was	  then	  prepared	  by	  pouring	  the	  
50°C	  warm	  gel	  solutions	  into	  horizontal	  trays	  with	  inserted	  combs	  (BioRad).	  The	  gel	  solidifies	  
at	  room	  temperature,	  generally	  in	  2h.	  Once	  the	  gel	  becomes	  solid	  we	  removed	  the	  combs.	  
The	   trays	   were	   placed	   in	   an	   electrophoresis	   chamber	   and	   covered	   with	   electrophoresis	  
buffer	   (the	   same	   buffer	   used	   to	   prepare	   the	   agarose	   solution).	   Electrophoresis	   was	  
performed	   at	   90	   V	   during	   40	   minutes	   (the	   time	   that	   the	   marker	   dye	   has	   migrated	   an	  
appropriate	  distance	  that	  depends	  on	  the	  size	  of	  the	  DNA	  fragments).	  	  
	  
	   	   	   	   	   	   	  	  
	   	   	   18	  
Gene	  expression	  analysis	  of	  public	  datasets	  
For	   this	   part	   of	   the	   experiment,	   we	   first	   determine	   expression	   of	   genes	   from	   a	   dataset	  
analysis	   using	   Gene	   Expression	  Omnibus	   (GEO)	   database.	   GEO	   is	   a	   public	   collection	   of	   all	  
published	   gene	   expression	   datasets.	   From	  GEO	  we	   selected	   a	   dataset	   including	   head	   and	  
neck	   squamous	   cell	   carcinoma	   (HNSCC)	   and	   cervical	   cancer	   samples	   with	   HPV	   status	  
(GSE6791	  dataset).	  From	  this	  dataset	  we	  selected	  all	  HPV	  positive	   (n=8)	  and	  HPV	  negative	  
(n=13)	  HNSCC	  samples	  for	  data	  analysis.	  Criteria's	  for	  groups’	  comparison	  were	  fold	  changes	  
and	   t-­‐test.	   Another	   dataset	   that	   we	   analyzed	   was	   the	   GSE24089	   dataset,	   which	   contains	  
expression	  data	  from	  HPV	  (-­‐)	  and	  HPV	  (+)	  squamous	  cell	  carcinoma	  cell	  lines:	  SCC4	  HPV	  (-­‐),	  
SCC74A	  HPV	   (-­‐),	   SCC47	  HPV	   (+)	   and	  CaSki	  HPV	   (+).	  CaSKi	   is	  originating	   from	  cervix	   cancer,	  
SCC4,	  SCC74A	  and	  SCC47	  are	  from	  HNSCC.	  Criteria's	  for	  groups’	  comparison	  were	  also	  fold	  
changes	  and	  t-­‐test.	  Then	  some	  genes	  up-­‐regulated	  in	  the	  HPV-­‐positive	  HNSCC	  samples	  and	  
HPV-­‐positive	  cell	  lines	  were	  selected	  for	  next	  qRT-­‐PCR	  analysis.	  
qRT-­‐PCR	  was	   performed	  on	   4	   selected	   cell	   lines	   and	   2	   tumour	   samples	   according	   to	   their	  
HPV	  status,	  origins	  and	  p53	  status.	  qRT-­‐PCR	  was	  performed	  using	  the	  SYBR	  Green	  assay.	  
Gene	  name	   Forward	  primer	  (5’-­‐3’)	   Reverse	  primer	  (5’-­‐3’)	  
SHISA2	   TGTCAGCAGGCCACCCAGATTG	   AGCTGTCATGGGCACAGAGTC	  
PARM1	   CAACTCGGTGCTCCCAGTTAC	   CGCTTGTTGACGAGAACCCA	  
TDRD9	   AAGAGCTTGATGTGTGTCGCA	   TGAGTGCTTTTACCGCTTCCC	  
TCAM1P	   GCAGCTCACCCATCAGAATAG	   TGGTCTTCCAGGAACATGTG	  
MEST	   AGGGACTGCGTATCTTCTACC	   ACCCGATGAAACCTCAAGGTC	  
HPRT1	  
(housekeeping	  gene)	  
TGACACTGGCAAAACAATGCA	   GGTCCTTTTCACCAGCAAGCT	  
	  
2.2.3.	  RNA	  methods	  
2.2.3.1.	   	  RNA	  preparation	  
Total	   RNA	  was	  prepared	   from	  cultured	   cells	   and	   tumor	   tissue	   samples	  with	   the	  Direct-­‐Zol	  
RNA	  mini	  Prep	  kit	  (Zymoresearch)	  according	  to	  the	  manufacturer's	   instructions.	  In	  order	  to	  
provide	  appropriate	  conditions	  for	  the	  binding	  of	  the	  RNA	  to	  the	  silica-­‐gel	  membrane	  of	  the	  
Zymo	   spin	   column,	  we	   added	   ethanol	   to	   the	   lysates.	   The	   samples	  were	   then	   treated	   on-­‐
column	  with	  RNase-­‐free	  DNase	  I	  to	  remove	  contaminating	  genomic	  DNA.	  RNAse-­‐free	  water	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was	  used	  to	  elute	  RNA	  from	  the	  membrane	  and	  recover	   it	   in	  a	  sterile	  tube.	  Then	  we	  used	  
Nanodrop	   spechtrophotometry	   (test	   type:	   nucleic	   acid)	   to	   evaluate	   and	   measure	   the	  
concentration	  and	  purity	  of	  RNA	  by	  measuring	  the	  absorbance	  at	  260	  nm	  and	  280	  nm.	  
	  
2.2.4.	   	   	  Protein	  methods	  
2.2.4.1.	   	  Protein	  determination	  by	  Bradford	  Protein	  Assay	  
Cell	   extracts	  were	  prepared	  using	  KLB-­‐buffer	   (1ml	  of	   complete	   lysis	   buffer	   for	   a	   confluent	  
T75	   cell	   culture	   flask).	   Cells	  were	   scraped	   in	   KLB-­‐buffer	   and	   incubated	   30	  minutes	   on	   ice,	  
then	   centrifugated	   for	   10	   minutes	   at	   4°C	   to	   peelt	   the	   debrisand	   the	   supernatant	   was	  
transfered	   in	  a	  1.5	  ml	   tube.	  To	  determine	   the	  protein	  concentration	  BCA	  protein	  assay	  kit	  
(Pierce)	   was	   used	   (spectrometry	   analysis	   at	   562	   nm	  wave-­‐length).	   Then	   we	   analyzed	   the	  
protein	   concentration	   using	   the	   Biotek	   Epoch	   Microplate	   Spectrophotometer	   and	   the	  
Gens1.10	  Software.	  
	  
2.2.4.2.	  	   SDS-­‐polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  
Standard	   SDS-­‐polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	   was	   carried	   out	   in	   Mini-­‐
Protean	   II	   dual	   slab	   cells	   (Bio-­‐Rad).	   For	   the	   resolving	   gel	   10%	  we	   prepared	   10	  ml	   that	   is	  
sufficient	  for	  small	  (8	  cm	  x	  10	  cm	  x	  1.5	  mm)	  gel	  format.	  For	  the	  5%	  stacking	  gel	  we	  prepared	  
3	   ml	   of	   gel	   solution.	   Both	   gels	   were	   prepared	   with	   SDS	   10	   %,	   TEMED	   and	   ammonium	  
persulfate	  were	  added	  just	  prior	  to	  pouring	  the	  gel.	  The	  separating	  gel	  solution	  was	  poured	  
into	  the	  assembled	  gel	  apparatus,	  overlaid	  with	  water	  and	  allowed	  to	  polymerize.	  After	  the	  
resolving	  gel	  had	  polymerized,	  we	  put	  10	  ul	  of	  isopropanolol	  on	  the	  gel	  surface	  and	  remove	  
with	  some	  blotting	  paper.	  Then	  we	  poured	  the	  staking	  gel	  and	  we	  inserted	  the	  combs	  and	  
wait	  for	  stacking	  gel	  polymerization.	  The	  protein	  samples	  were	  prepared	  by	  heating	  them	  1	  
minute	  at	  95°C.	  The	  gel	  was	  run	  at	  a	  constant	  voltage	  of	  100V	  for	  1h15.	  
	  
2.2.4.3.	   	  Western	  blotting	  
Western	  Blotting	  was	  then	  performed	  on	  4	  selected	  cell	  lines	  according	  to	  their	  HPV	  status,	  
origins	  and	  p53	  status.	  HPV	  positive	  head	  and	  neck	  cancer	   cell	   line	  was	  also	   selected	  as	  a	  
positive	  control	  comparison.	  Two	  proteins	  were	  selected	  for	  Western	  Blotting	  analysis	  of	  cell	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lysates:	   rabbit	   polyclonal	   anti-­‐SHISA2	   antibody	   (cat.	   N.	   PA5-­‐25853)	   was	   purchased	   from	  
Pierce.	  
The	  polyacrylamide	  gel	  was	  sandwiched	  between	  two	  layers	  of	  filter	  paper	  and	  two	  sponges	  
in	   a	   cassette.	   Electrophoretic	   transfer	   of	   proteins	   to	   nitrocellulose	   sheets	   was	   performed	  
using	   a	  Mini	   Protean	   II	   transfer	   system	   (Biorad).	   The	   nitrocellulose	   sheet	   (Protran	   BA-­‐85,	  
0.45	   μm),	   filter	   paper	   and	   sponges	  were	   first	   soaked	   in	   the	   transfer	   buffer.	  We	   removed	  
then	   the	   gel	   from	   the	   electrophoresis	   chamber	   and	   removed	   the	   upper	   part	   of	   the	   gel	  
(stacking	   gel),	   always	   with	   liquid	   to	   not	   dry	   the	   gel.	   The	   gel	   was	   equilibrated	   with	   the	  
transfer	  buffer.	  After	  assembling	  of	  gel/nitrocellulose	  membrane	  sandwiched	  between	  filter	  
papers	  and	   foam	  pads	   in	  a	   special	   cassette,	   the	  cassette	  was	  placed	   inside	  of	   the	   support	  
frame	   of	   the	   transfer	   cell	   such	   that	   the	   nitrocellulose	   side	   of	   the	   stack	   was	   towards	   the	  
positive	  pole,	  because	  protein	  are	  negatively	  charged	  and	  will	  run	  from	  the	  positive	  to	  the	  
negative	   pole.	   The	   cooling	   box	   filled	   with	   ice	   was	   inserted	   into	   the	   apparatus	   and	   the	  
appropriate	   volume	   of	   transfer	   buffer	   was	   added.	   The	   transfer	   was	   performed	   for	   75	  
minutes	   at	   100V.	   After	   completion	   of	   the	   electrotransfer,	   the	   power	   was	   turned	   off,	   the	  
apparatus	  was	  disassembled,	  and	  the	  nitrocellulose	  filter	  was	  removed	  and	  briefly	  dried.	  
To	  reduce	  non-­‐specific	  binding	  of	  antibody	  (that	  will	  be	  used	  for	  the	  detection	  of	  the	  target	  
protein),	  the	  nitrocellulose	  membrane	  was	  incubated	  in	  a	  5%	  milk-­‐solution	  by	  continuously	  
agitating	  it	  on	  a	  rocking	  platform	  for	  at	  least	  60	  min	  at	  room	  temperature	  (5%	  non-­‐fat	  milk	  in	  
PBS/0.1%	  Tween	  20=	  blocking	  buffer).	  We	  prepared	  the	  primary	  antibody	  solution	  by	  adding	  
antibody	  solution	  in	  2.5%	  milk	  in	  PBS/0.1%Tween	  20.	  Then	  we	  took	  the	  membrane	  and	  rinse	  
it	  with	  PBS/0.1%Tween	  20	  and	  put	  it	  in	  a	  Falcon	  tube	  with	  the	  protein	  face	  inward	  the	  tube	  
and	  we	   let	   it	   incubate	  with	   the	   primary	   antibody	   solution	   overnight	   in	   a	   cold	   room	   on	   a	  
mixer	  plate.	  After	  3	  washes	  (15	  min	  each)	  with	  PBS/0.1%	  Tween	  20,	  the	  blot	  was	  incubated	  
for	  1	  h	  with	  the	  horseradish	  peroxidase-­‐labelled	  secondary	  antibody	  diluted	  in	  the	  2.5%	  milk	  
solution.	   The	   appropriate	   titers	   of	   primary	   and	   secondary	   antibodies	   varied	   and	   were	  
determined	   in	  preliminary	  experiments.	  We	  used	  as	  dilutions	  1:100	   for	  primary	  antibodies	  
and	  1:2500	  for	  secondary	  antibodies.	  After	  that,	  the	  nitrocellulose	  sheet	  was	  again	  washed	  3	  
times	   8	   minutes	   and	   incubated	   with	   the	   luminol-­‐based	   ECL	   Western	   blotting	   detection	  
reagents	  from	  Pierce	  (SuperSignal	  West	  Pico).	  We	  incubated	  the	  membrane	  5	  minutes,	  and	  
then	   we	   dry	   the	   membrane	   and	   put	   it	   in	   the	   RX-­‐detection	   box.	   Light	   generated	   by	   the	  
chemiluminescent	  reaction	  was	  detected	  by	  exposing	  X-­‐ray	  film	  (Fuji).	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3.	  Results	  
3.1.	  Multiplexed	  RT-­‐PCR	  method	  for	  detection	  of	  HPV	  transcripts	  in	  tumor	  samples	  
and	  cell	  lines	  
RNA	  from	  40	  tumor	  samples	  originating	  from	  oral	  cavity	  and	  oropharynx	  were	  collected	  at	  
the	   CHUV	   (Centre	   Hospitalier	   Universitaire	   Vaudois).	   All	   surgical	   tumor	   samples	   were	  
collected	  before	  any	  previous	  adjuvant	  treatments	  (radiotherapy	  or	  chemotherapy).	  40	  RNA	  
samples	   have	   been	   converted	   into	   cDNA,	   which	   were	   pooled	   into	   8	   groups	   containing	   5	  
cDNA	   samples.	   Sample	   pooling	   was	   done	   to	   reduce	   the	   number	   of	   PCR	   amplifications,	  
because	  low	  frequency	  of	  HPV-­‐expressing	  tumor	  samples	  was	  expected.	  Other	  RNA	  samples	  
were	   derived	   from	   head	   and	   neck	   cancer	   cell	   lines	   established	   in	   the	   ORL	   lab	   were	   also	  
converted	  into	  cDNA	  and	  tested	  by	  PCR	  for	  the	  presence	  of	  HPV	  transcripts.	  To	  control	  the	  
specificity	   of	   the	  designed	  primers	  we	  used	   as	   a	   positive	   control,	   cDNA	   from	  human	  Hela	  
cells	  that	  express	  HPV	  18	  transcripts	  and	  mouse	  TC-­‐1	  cells	  that	  express	  HPV	  16	  transcripts.	  In	  
addition,	  genomic	  DNA	  of	  HPV	  56	  subtype	  (kindly	  provided	  by	  Dr.	  Roland	  Sahli,	  CHUV)	  was	  
used	   as	   control	   for	   HPV56-­‐specific	   primers.	   Multiplexed	   PCR	   amplification	   was	   used	   for	  
detection	  of	  expressed	  HPV	  transcripts.	  Four	  primer	  pairs	  specific	  for	  HPV	  16,	  HPV18,	  HPV33,	  
HPV56,	   designed	   by	   Dr.	   Genrich	   Tolstonog	   and	   described	   in	   the	   material	   and	   methods	  
section,	  were	   used.	   Design	   of	   primers	  was	   done	   to	   detect	   by	   agarose	   gel	   electrophoresis	  
four	  HPV	  isotypes	  based	  on	  the	  difference	  in	  size	  (base	  pair)	  of	  the	  amplified	  PCR	  products:	  
84	  bps	  for	  HPV-­‐18,	  109	  bps	  for	  HPV-­‐16,	  136	  bps	  for	  HPV-­‐56	  and	  173	  bps	  for	  HPV-­‐33.	  
We	  proceeded	  in	  two	  steps.	  In	  the	  first	  step	  the	  eight	  pools	  were	  tested	  by	  PCR.	  	  We	  found	  
that	   one	   of	   the	   samples	  was	  HPV-­‐33	   positive	   (Figure	   5-­‐A).	   Therefore,	  we	   tested	   then	   the	  
individual	  samples	  of	  this	  pool	  separately	  and	  found	  that	  HPV-­‐33	  transcipts	  are	  detectable	  in	  
patient	  number	  25,	  which	  was	  a	  tumor	  sample	  collected	  in	  the	  oral	  cavity	  (Figure	  5-­‐B).	  This	  
sample	  will	  be	  used	  for	  testing	  of	  genes	  from	  a	  bioinformatic	  analysis.	  In	  the	  second	  step,	  we	  
tested	  the	  cell	  lines	  established	  in	  the	  ORL	  lab	  also	  by	  using	  PCR	  and	  the	  four	  primers	  pairs.	  	  
As	  shown	  in	  Figure	  5-­‐C,	  no	  cell	  lines	  express	  HPV	  subtypes	  16,	  18,	  33	  and	  56.	  	  
	  
	   	   	   	   	   	   	  	  














3.2.	  Bioinformatics	  gene	  expression	  analysis	  of	  HNSCC	  tumor	  samples	  and	  cell	  lines	  
with	  known	  HPV	  status	  
In	  order	  to	  identify	  genes	  which	  expression	  correlates	  with	  the	  HPV	  status	  of	  tumors	  and	  is	  
specifically	   expressed	   in	   HPV-­‐positive	   cancer	   cell	   lines,	   we	   took	   advantage	   of	   the	   GEO	  
database	   that	   is	   a	   public	   collection	   of	   gene	   expression	   datasets.	   From	   GEO	   database	   we	  
selected	  GSE6791	  dataset	  that	  includes	  HNSCC	  and	  cervical	  cancer	  samples	  with	  known	  HPV	  
status.	   For	  bioinformatic	   study	  we	  used	  gene	  expression	  data	   from	  8	  HPV-­‐positive	  and	  13	  
HPV-­‐negative	   samples	   in	   the	   GSE6791	   dataset,	   and	   we	   applied	   the	   following	   criteria	   for	  
group	   comparison:	   fold	   change	   (more	   than	   2	   fold)	   and	   t-­‐test	   (p	   <	   0.05).	   This	   analysis	   has	  
shown	  that	  101	  genes	  represented	  by	  137	  Affymetrix	  probesets	  are	  differentially	  expressed	  
between	  HPV-­‐positive	   and	  HPV-­‐negative	  HNC	   samples:	   48	   genes	   are	   up-­‐regulated	   and	   53	  
genes	  are	  down-­‐regulated	  in	  the	  HPV-­‐positive	  tumor	  samples	  (Table	  1	  and	  2).	  As	  expected,	  
the	   list	   of	   the	   top-­‐regulated	   genes	   includes	   CDKN2A	   gene,	   which	   encodes	   p16	   protein,	   a	  
surrogate	  marker	  of	  HPV-­‐positive	  head	  and	  neck	  tumors.	  From	  the	   list	  of	  the	  up-­‐regulated	  








Figure	  5:	  Detection	  of	  HPV	  transcripts	  in	  tumor	  samples	  biopsies.	  A)	  PCR	  performed	  on	  the	  8	  (5	  samples)	  pools	  of	  
40	   cDNA	   samples.	   3	   positive	   controls	   (9:	   HPV56	   genomic	   DNA;11:	   HPV18	   transcripts	   in	   Hela	   cells;12:	   HPV16	  
transcripts	  in	  TC-­‐1	  cells)	  and	  one	  negative	  control	  (10:	  water	  control)	  have	  been	  used.	  Positive	  signal	  for	  HPV-­‐33	  
(173	  bps)	  is	  in	  the	  pool	  number	  5.	  B)	  PCR	  performed	  on	  the	  5	  samples	  from	  the	  pool	  number	  5.	  Positive	  signal	  for	  
HPV-­‐33	  (173bps)	  in	  the	  biopsies	  number	  5.	  C)	  PCR	  performed	  on	  cDNA	  from	  the	  head	  and	  neck	  cancer	  cell	  lines	  
(1-­‐14).	  3	  positive	  controls	  (15:	  HPV33	  genomic	  DNA;	  16:	  HPV16	  transcripts	  in	  TC-­‐1	  cells;	  17:	  HPV18	  transcripts	  in	  
Hela	  cells	  ),	  1	  negative	  control	  (18:	  water	  control).	  No	  detection	  of	  HPV	  transcripts	   in	  the	  tested	  cell	  lines.	  Band	  
detected	  in	  most	  samples	  including	  water	  control	  represent	  primer	  dimers.	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Table	  1:	  List	  of	  genes	  up-­‐regulated	  in	  HPV-­‐positive	  samples	  from	  the	  GSE6791	  dataset	  
probeid	   symbol	   NAME	   LogFC	   adj.pvalue	  
230493_at	   SHISA2	   shisa	  homolog	  2	  (Xenopus	  laevis)	   4.10	   6.67E-­‐08	  
227662_at	   SYNPO2	   synaptopodin	  2	   4.00	   1.70E-­‐07	  
233320_at	   TCAM1P	   testicular	  cell	  adhesion	  molecule	  1	  homolog	  (mouse),	  pseudogene	   3.36	   5.74E-­‐15	  
231164_at	   ABCA17P	   ATP-­‐binding	  cassette,	  sub-­‐family	  A	  (ABC1),	  member	  17,	  pseudogene	   3.29	   4.16E-­‐12	  
206546_at	   SYCP2	   synaptonemal	  complex	  protein	  2	   3.26	   3.94E-­‐08	  
203881_s_at	   DMD	   dystrophin	   3.25	   6.04E-­‐07	  
235343_at	   VASH2	   vasohibin	  2	   3.24	   2.08E-­‐05	  
229623_at	   TMEM150C	   transmembrane	  protein	  150C	   3.20	   4.41E-­‐06	  
203868_s_at	   VCAM1	   vascular	  cell	  adhesion	  molecule	  1	   3.19	   2.17E-­‐07	  
201650_at	   KRT19	   keratin	  19	   3.13	   1.40E-­‐03	  
1557570_a_at	   LOC285084	   hypothetical	  protein	  LOC285084	   3.05	   2.09E-­‐09	  
205890_s_at	   NA	   NA	   2.94	   1.33E-­‐07	  
207039_at	   CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A	  (melanoma,	  p16,	  inhibits	  CDK4)	   2.94	   1.71E-­‐04	  
229152_at	   C4orf7	   chromosome	  4	  open	  reading	  frame	  7	   2.86	   4.56E-­‐03	  
228434_at	   BTNL9	   butyrophilin-­‐like	  9	   2.84	   2.94E-­‐09	  
1556244_s_at	   LOC375196	   hypothetical	  protein	  LOC375196	   2.70	   1.25E-­‐10	  
204798_at	   MYB	   v-­‐myb	  myeloblastosis	  viral	  oncogene	  homolog	  (avian)	   2.67	   1.94E-­‐06	  
227702_at	   CYP4X1	   cytochrome	  P450,	  family	  4,	  subfamily	  X,	  polypeptide	  1	   2.53	   1.89E-­‐04	  
225809_at	   PARM1	   prostate	  androgen-­‐regulated	  mucin-­‐like	  protein	  1	   2.52	   6.45E-­‐07	  
1569040_s_at	   FLJ40330	   hypothetical	  LOC645784	   2.50	   5.33E-­‐05	  
202437_s_at	   CYP1B1	   cytochrome	  P450,	  family	  1,	  subfamily	  B,	  polypeptide	  1	   2.50	   1.65E-­‐03	  
217028_at	   CXCR4	   chemokine	  (C-­‐X-­‐C	  motif)	  receptor	  4	   2.41	   2.52E-­‐06	  
1557545_s_at	   RNF165	   ring	  finger	  protein	  165	   2.35	   1.42E-­‐06	  
215028_at	   SEMA6A	   semaphorin	  6A	   2.35	   6.76E-­‐06	  
205668_at	   LY75	   lymphocyte	  antigen	  75	   2.35	   5.61E-­‐06	  
228262_at	   MAP7D2	   MAP7	  domain	  containing	  2	   2.34	   2.36E-­‐08	  
210538_s_at	   BIRC3	   baculoviral	  IAP	  repeat-­‐containing	  3	   2.34	   1.77E-­‐04	  
204409_s_at	   EIF1AY	   eukaryotic	  translation	  initiation	  factor	  1A,	  Y-­‐linked	   2.32	   1.24E-­‐02	  
203685_at	   BCL2	   B-­‐cell	  CLL/lymphoma	  2	   2.30	   6.46E-­‐06	  
226811_at	   FAM46C	   family	  with	  sequence	  similarity	  46,	  member	  C	   2.29	   4.19E-­‐05	  
1556300_s_at	   SIM1	   single-­‐minded	  homolog	  1	  (Drosophila)	   2.29	   5.82E-­‐05	  
205267_at	   POU2AF1	   POU	  class	  2	  associating	  factor	  1	   2.25	   9.79E-­‐04	  
204533_at	   CXCL10	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  10	   2.23	   3.77E-­‐05	  
222940_at	   SULT1E1	   sulfotransferase	  family	  1E,	  estrogen-­‐preferring,	  member	  1	   2.19	   1.38E-­‐03	  
234994_at	   TMEM200A	   transmembrane	  protein	  200A	   2.18	   5.61E-­‐04	  
205159_at	   CSF2RB	   colony	  stimulating	  factor	  2	  receptor,	  beta,	  low-­‐affinity	   2.16	   1.15E-­‐06	  
213131_at	   OLFM1	   olfactomedin	  1	   2.15	   2.47E-­‐05	  
205681_at	   BCL2A1	   BCL2-­‐related	  protein	  A1	   2.14	   5.15E-­‐04	  
209583_s_at	   CD200	   CD200	  molecule	   2.12	   9.86E-­‐06	  
209708_at	   MOXD1	   monooxygenase,	  DBH-­‐like	  1	   2.11	   2.89E-­‐05	  
205242_at	   CXCL13	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  13	   2.10	   3.27E-­‐03	  
233064_at	   ZFR2	   zinc	  finger	  RNA	  binding	  protein	  2	   2.10	   5.19E-­‐12	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228174_at	   SCAI	   suppressor	  of	  cancer	  cell	  invasion	   2.09	   7.33E-­‐06	  
214669_x_at	   IGKC	   immunoglobulin	  kappa	  constant	   2.08	   6.92E-­‐05	  
218824_at	   PNMAL1	   PNMA-­‐like	  1	   2.08	   6.41E-­‐06	  
210072_at	   CCL19	   chemokine	  (C-­‐C	  motif)	  ligand	  19	   2.06	   1.24E-­‐04	  
205328_at	   CLDN10	   claudin	  10	   2.04	   1.17E-­‐05	  
209289_at	   NFIB	   nuclear	  factor	  I/B	   2.04	   7.22E-­‐04	  
242539_at	   DIS3L2	   DIS3	  mitotic	  control	  homolog	  (S.	  cerevisiae)-­‐like	  2	   2.02	   1.63E-­‐04	  
 
Table	  2:	  List	  of	  genes	  down-­‐regulated	  in	  HPV-­‐positive	  samples	  from	  the	  GSE6791	  dataset	  
probeid	   symbol	   NAME	   LogFC	   adj.pvalue	  
209160_at	   AKR1C3	   aldo-­‐keto	  reductase	  family	  1,	  member	  C3	   -­‐4.26	   8.98E-­‐06	  
206561_s_at	   AKR1B10	  
aldo-­‐keto	  reductase	  family	  1,	  member	  B10	  (aldose	  
reductase)	   -­‐3.91	   8.45E-­‐09	  
213506_at	   F2RL1	   coagulation	  factor	  II	  (thrombin)	  receptor-­‐like	  1	   -­‐3.64	   6.68E-­‐12	  
205916_at	   S100A7	   S100	  calcium	  binding	  protein	  A7	   -­‐3.62	   1.96E-­‐04	  
223631_s_at	   C19orf33	   chromosome	  19	  open	  reading	  frame	  33	   -­‐3.53	   4.51E-­‐05	  
219263_at	   RNF128	   ring	  finger	  protein	  128	   -­‐3.44	   8.09E-­‐08	  
211906_s_at	   SERPINB4	   serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  4	   -­‐3.25	   4.90E-­‐04	  
206166_s_at	   CLCA2	   chloride	  channel	  accessory	  2	   -­‐3.18	   1.28E-­‐05	  
231771_at	   GJB6	   gap	  junction	  protein,	  beta	  6,	  30kDa	   -­‐3.12	   7.51E-­‐04	  
202345_s_at	   FABP5	   fatty	  acid	  binding	  protein	  5	  (psoriasis-­‐associated)	   -­‐3.04	   2.96E-­‐07	  
230835_at	   KRTDAP	   keratinocyte	  differentiation-­‐associated	  protein	   -­‐3.00	   4.08E-­‐03	  
206300_s_at	   PTHLH	   parathyroid	  hormone-­‐like	  hormone	   -­‐2.99	   4.29E-­‐07	  
214612_x_at	   MAGEA6	   melanoma	  antigen	  family	  A,	  6	   -­‐2.94	   2.05E-­‐03	  
213796_at	   SPRR1A	   small	  proline-­‐rich	  protein	  1A	   -­‐2.88	   4.24E-­‐03	  
209699_x_at	   AKR1C2	   aldo-­‐keto	  reductase	  family	  1,	  member	  C2	   -­‐2.88	   1.06E-­‐05	  
209800_at	   KRT16	   keratin	  16	   -­‐2.67	   2.69E-­‐03	  
222484_s_at	   CXCL14	   chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  14	   -­‐2.67	   1.80E-­‐05	  
205064_at	   SPRR1B	   small	  proline-­‐rich	  protein	  1B	   -­‐2.66	   3.35E-­‐03	  
209719_x_at	   SERPINB3	   serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  3	   -­‐2.63	   3.56E-­‐04	  
226926_at	   DMKN	   dermokine	   -­‐2.61	   2.11E-­‐03	  
209301_at	   CA2	   carbonic	  anhydrase	  II	   -­‐2.56	   3.52E-­‐05	  
223278_at	   GJB2	   gap	  junction	  protein,	  beta	  2,	  26kDa	   -­‐2.49	   3.14E-­‐04	  
210503_at	   MAGEA11	   melanoma	  antigen	  family	  A,	  11	   -­‐2.48	   1.57E-­‐03	  
209942_x_at	   MAGEA3	   melanoma	  antigen	  family	  A,	  3	   -­‐2.47	   2.52E-­‐03	  
204469_at	   PTPRZ1	  
protein	  tyrosine	  phosphatase,	  receptor-­‐type,	  Z	  polypeptide	  
1	   -­‐2.47	   2.18E-­‐04	  
214073_at	   CTTN	   cortactin	   -­‐2.45	   3.90E-­‐05	  
203980_at	   FABP4	   fatty	  acid	  binding	  protein	  4,	  adipocyte	   -­‐2.44	   2.47E-­‐03	  
202990_at	   PYGL	   phosphorylase,	  glycogen,	  liver	   -­‐2.30	   4.23E-­‐08	  
227736_at	   C10orf99	   chromosome	  10	  open	  reading	  frame	  99	   -­‐2.28	   1.96E-­‐02	  
203963_at	   CA12	   carbonic	  anhydrase	  XII	   -­‐2.27	   2.29E-­‐06	  
219795_at	   SLC6A14	   solute	  carrier	  family	  6	  (amino	  acid	  transporter),	  member	  14	   -­‐2.27	   2.88E-­‐03	  
1562102_at	   AKR1C1	   aldo-­‐keto	  reductase	  family	  1,	  member	  C1	   -­‐2.24	   5.36E-­‐04	  
211361_s_at	   SERPINB13	   serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  13	   -­‐2.23	   8.65E-­‐03	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210519_s_at	   NQO1	   NAD(P)H	  dehydrogenase,	  quinone	  1	   -­‐2.19	   1.74E-­‐05	  
1558378_a_at	   AHNAK2	   AHNAK	  nucleoprotein	  2	   -­‐2.19	   7.18E-­‐04	  
209351_at	   KRT14	   keratin	  14	   -­‐2.18	   1.65E-­‐03	  
1552487_a_at	   BNC1	   basonuclin	  1	   -­‐2.17	   9.60E-­‐05	  
205680_at	   MMP10	   matrix	  metallopeptidase	  10	  (stromelysin	  2)	   -­‐2.17	   4.08E-­‐04	  
226863_at	   FAM110C	   family	  with	  sequence	  similarity	  110,	  member	  C	   -­‐2.17	   3.18E-­‐05	  
206354_at	   SLCO1B3	  
solute	  carrier	  organic	  anion	  transporter	  family,	  member	  
1B3	   -­‐2.13	   3.63E-­‐04	  
203324_s_at	   CAV2	   caveolin	  2	   -­‐2.12	   4.01E-­‐06	  
203851_at	   IGFBP6	   insulin-­‐like	  growth	  factor	  binding	  protein	  6	   -­‐2.12	   5.61E-­‐04	  
209126_x_at	   KRT6B	   keratin	  6B	   -­‐2.10	   9.42E-­‐03	  
203535_at	   S100A9	   S100	  calcium	  binding	  protein	  A9	   -­‐2.09	   1.68E-­‐02	  
232170_at	   S100A7A	   S100	  calcium	  binding	  protein	  A7A	   -­‐2.09	   3.04E-­‐03	  
204058_at	   ME1	   malic	  enzyme	  1,	  NADP(+)-­‐dependent,	  cytosolic	   -­‐2.07	   1.35E-­‐05	  
201427_s_at	   SEPP1	   selenoprotein	  P,	  plasma,	  1	   -­‐2.07	   1.29E-­‐04	  
231726_at	   PCDHB14	   protocadherin	  beta	  14	   -­‐2.07	   8.56E-­‐06	  
228698_at	   SOX7	   SRY	  (sex	  determining	  region	  Y)-­‐box	  7	   -­‐2.06	   6.73E-­‐05	  
227202_at	   CNTN1	   contactin	  1	   -­‐2.06	   2.57E-­‐03	  
204388_s_at	   MAOA	   monoamine	  oxidase	  A	   -­‐2.04	   8.35E-­‐04	  
202376_at	   SERPINA3	   serpin	  peptidase	  inhibitor,	  clade	  A,	  member	  3	   -­‐2.04	   9.91E-­‐04	  
	  
The	  GSE24089	  dataset	  was	  used	  to	  analyze	  expression	  data	  from	  the	  HPV-­‐negative	  and	  HPV-­‐
positive	  squamous	  cell	  carcinoma	  cell	  lines:	  SCC4	  HPV	  (-­‐),	  SCC74A	  HPV	  (-­‐),	  SCC47	  HPV	  (+)	  and	  
CaSki	  HPV	   (+).	   SCC4,	  SCC47	  and	  SCC74A	  cell	   lines	  are	  derived	   from	  head	  and	  neck	  cancer,	  
while	  CaSKi	  cell	  line	  is	  derived	  from	  cervical	  cancer.	  Using	  the	  same	  criteria's	  for	  comparison	  
of	   groups	   (fold	   change	   more	   than	   2	   fold)	   and	   t-­‐test:	   p	   <	   0.05)	   we	   found	   that	   63	   genes	  
represented	  by	  74	  Affymetrix	  probesets	  are	  differentially	  expressed	  between	  HPV-­‐positive	  
and	  HPV-­‐negative	  cell	  lines:	  39	  genes	  are	  up-­‐regulated	  and	  24	  genes	  are	  down-­‐regulated	  in	  
the	  HPV-­‐positive	  cell	  lines	  (Table	  3	  and	  4).	  Also	  this	  analysis	  has	  shown	  that	  CDKN2A	  gene	  is	  
prominently	   up-­‐regulated	   in	   the	   HPV-­‐positive	   cell	   lines.	   For	   the	   next	   experiments	   we	  
selected	  some	  top	  up-­‐regulated	  genes.	  
	  
Table	  3:	  List	  of	  genes	  up-­‐regulated	  in	  HPV-­‐positive	  cell	  lines	  from	  the	  GSE24089	  dataset	  
probeid	   symbol	   NAME	   LogFC	   adj.pvalue	  
228285_at	   TDRD9	   tudor	  domain	  containing	  9	   6.42	   0.0016	  
224918_x_at	   MGST1	   microsomal	  glutathione	  S-­‐transferase	  1	   6.19	   0.0276	  
205466_s_at	   HS3ST1	   heparan	  sulfate	  (glucosamine)	  3-­‐O-­‐sulfotransferase	  1	   6.06	   0.0023	  
204614_at	   SERPINB2	   serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  2	   5.81	   0.0062	  
209278_s_at	   TFPI2	   tissue	  factor	  pathway	  inhibitor	  2	   5.75	   0.0022	  
200953_s_at	   CCND2	   cyclin	  D2	   5.71	   0.0217	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207039_at	   CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A	  (melanoma,	  p16,	  inhibits	  CDK4)	   5.60	   0.0026	  
215729_s_at	   VGLL1	   vestigial	  like	  1	  (Drosophila)	   5.58	   0.0041	  
234973_at	   SLC38A5	   solute	  carrier	  family	  38,	  member	  5	   5.52	   0.0019	  
219836_at	   ZBED2	   zinc	  finger,	  BED-­‐type	  containing	  2	   5.24	   0.0062	  
222242_s_at	   KLK5	   kallikrein-­‐related	  peptidase	  5	   5.19	   0.0133	  
244050_at	   PTPLAD2	   protein	  tyrosine	  phosphatase-­‐like	  A	  domain	  containing	  2	   5.17	   0.0133	  
223861_at	   HORMAD1	   HORMA	  domain	  containing	  1	   5.14	   0.0062	  
227850_x_at	   CDC42EP5	   CDC42	  effector	  protein	  (Rho	  GTPase	  binding)	  5	   5.10	   0.0031	  
202016_at	   MEST	   mesoderm	  specific	  transcript	  homolog	  (mouse)	   5.08	   0.0042	  
219181_at	   LIPG	   lipase,	  endothelial	   5.04	   0.0146	  
1552797_s_at	   PROM2	   prominin	  2	   4.97	   0.0276	  
213113_s_at	   SLC43A3	   solute	  carrier	  family	  43,	  member	  3	   4.85	   0.0486	  
210118_s_at	   IL1A	   interleukin	  1,	  alpha	   4.78	   0.0053	  
206595_at	   CST6	   cystatin	  E/M	   4.76	   0.0133	  
226847_at	   FST	   follistatin	   4.73	   0.0276	  
220027_s_at	   RASIP1	   Ras	  interacting	  protein	  1	   4.63	   0.0117	  
223784_at	   TMEM27	   transmembrane	  protein	  27	   4.62	   0.0241	  
204465_s_at	   INA	   internexin	  neuronal	  intermediate	  filament	  protein,	  alpha	   4.61	   0.0166	  
205206_at	   KAL1	   Kallmann	  syndrome	  1	  sequence	   4.60	   0.0090	  
221648_s_at	   NA	   NA	   4.52	   0.0133	  
207517_at	   LAMC2	   laminin,	  gamma	  2	   4.34	   0.0133	  
238439_at	   ANKRD22	   ankyrin	  repeat	  domain	  22	   4.28	   0.0133	  
233320_at	   TCAM1P	   testicular	  cell	  adhesion	  molecule	  1	  homolog	  (mouse),	  pseudogene	   4.15	   0.0241	  
236918_s_at	   LRRC34	   leucine	  rich	  repeat	  containing	  34	   4.01	   0.0486	  
210550_s_at	   RASGRF1	   Ras	  protein-­‐specific	  guanine	  nucleotide-­‐releasing	  factor	  1	   3.98	   0.0449	  
208291_s_at	   TH	   tyrosine	  hydroxylase	   3.92	   0.0242	  
229332_at	   HPDL	   4-­‐hydroxyphenylpyruvate	  dioxygenase-­‐like	   3.88	   0.0241	  
1559607_s_at	   GBP6	   guanylate	  binding	  protein	  family,	  member	  6	   3.87	   0.0342	  
226145_s_at	   FRAS1	   Fraser	  syndrome	  1	   3.83	   0.0347	  
226132_s_at	   MANEAL	   mannosidase,	  endo-­‐alpha-­‐like	   3.82	   0.0276	  
210038_at	   PRKCQ	   protein	  kinase	  C,	  theta	   3.78	   0.0276	  
1556244_s_at	   LOC375196	   hypothetical	  protein	  LOC375196	   3.77	   0.0418	  
211712_s_at	   ANXA9	   annexin	  A9	   3.53	   0.0404	  
 
Table	  4:	  List	  of	  genes	  down-­‐regulated	  in	  HPV-­‐positive	  cell	  lines	  from	  the	  GSE24089	  dataset	  
probeid	   symbol	   NAME	   LogFC	   adj.pvalue	  
204597_x_at	   STC1	   stanniocalcin	  1	   -­‐7.18	   0.0003	  
201744_s_at	   LUM	   lumican	   -­‐5.96	   0.0016	  
204337_at	   RGS4	   regulator	  of	  G-­‐protein	  signaling	  4	   -­‐5.72	   0.0241	  
219288_at	   C3orf14	   chromosome	  3	  open	  reading	  frame	  14	   -­‐5.66	   0.0019	  
221730_at	   COL5A2	   collagen,	  type	  V,	  alpha	  2	   -­‐5.58	   0.0062	  
213425_at	   WNT5A	   wingless-­‐type	  MMTV	  integration	  site	  family,	  member	  5A	   -­‐5.57	   0.0296	  
212094_at	   PEG10	   paternally	  expressed	  10	   -­‐5.52	   0.0019	  
205767_at	   EREG	   epiregulin	   -­‐5.42	   0.0241	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206172_at	   IL13RA2	   interleukin	  13	  receptor,	  alpha	  2	   -­‐5.41	   0.0313	  
218573_at	   MAGEH1	   melanoma	  antigen	  family	  H,	  1	   -­‐4.91	   0.0041	  
226875_at	   DOCK11	   dedicator	  of	  cytokinesis	  11	   -­‐4.62	   0.0090	  
230563_at	   RASGEF1A	   RasGEF	  domain	  family,	  member	  1A	   -­‐4.55	   0.0174	  
226051_at	   SELM	   selenoprotein	  M	   -­‐4.50	   0.0296	  
219985_at	   HS3ST3A1	   heparan	  sulfate	  (glucosamine)	  3-­‐O-­‐sulfotransferase	  3A1	   -­‐4.45	   0.0174	  
209230_s_at	   NUPR1	   nuclear	  protein,	  transcriptional	  regulator,	  1	   -­‐4.26	   0.0276	  
211653_x_at	   AKR1C2	  
aldo-­‐keto	  reductase	  family	  1,	  member	  C2	  (dihydrodiol	  
dehydrogenase	  2	   -­‐4.19	   0.0276	  
205741_s_at	   DTNA	   dystrobrevin,	  alpha	   -­‐3.99	   0.0312	  
218638_s_at	   SPON2	   spondin	  2,	  extracellular	  matrix	  protein	   -­‐3.95	   0.0497	  
212154_at	   SDC2	   syndecan	  2	   -­‐3.92	   0.0217	  
204151_x_at	   AKR1C1	  
aldo-­‐keto	  reductase	  family	  1,	  member	  C1	  (dihydrodiol	  
dehydrogenase	  1	   -­‐3.85	   0.0486	  
231725_at	   PCDHB2	   protocadherin	  beta	  2	   -­‐3.70	   0.0347	  
232195_at	   GPR158	   G	  protein-­‐coupled	  receptor	  158	   -­‐3.70	   0.0325	  
209160_at	   AKR1C3	   aldo-­‐keto	  reductase	  family	  1,	  member	  C3	   -­‐3.67	   0.0486	  
210102_at	   VWA5A	   von	  Willebrand	  factor	  A	  domain	  containing	  5A	   -­‐3.65	   0.0347	  
 
At	  this	  point	  the	  selected	  5	  genes	  for	  further	  validation	  by	  qRT-­‐PCR:	  SHISA2	  (up-­‐regulated	  in	  
HPV-­‐positive	   samples	   from	   the	   GSE6791	   dataset),	   PARM1	   (up-­‐regulated	   in	   HPV-­‐positive	  
samples	  from	  the	  GSE6791	  dataset),	  TDRD9	  (up-­‐regulated	  in	  HPV-­‐positive	  samples	  from	  the	  
GSE24089	   dataset),	   TCAMP1	   (up-­‐regulated	   in	   HPV-­‐positive	   samples	   from	   the	   GSE6791	  
dataset)	  and	  MEST	  (up-­‐regulated	  in	  HPV-­‐positive	  samples	  from	  the	  GSE24089	  dataset).	  	  
Shisa	   family	  member	  2	   (SHISA2)	  gene	  encodes	  a	  protein	  that	  plays	  an	  essential	   role	   in	   the	  
maturation	   of	   mesoderm	   cells	   by	   individual	   attenuation	   of	   both	   FGF	   and	  WNT	   signaling.	  
Prostate	  Androgen-­‐Regulated	  Mucin-­‐Like	  Protein	  1	  (PARM1)	  is	  a	  protein-­‐coding	  gene	  which	  
function	   has	   an	   implication	   in	   the	   regulation	   of	   telomerase	   activity,	   that	   enabling	   certain	  
prostate	   epithelial	   cells	   to	   resist	   apoptosis.	   PARM1	   is	   also	   known	   to	   be	   associated	   with	  
certain	   diseases	   including	   epispadias.	   Tudor	   Domain	   Containing	   9	   (TDRD9)	   is	   a	   protein-­‐
coding	   gene.	   It	   has	   a	   putative	   ATP-­‐binding	   RNA	   helicase	   activity	   that	   plays	   a	   role	   during	  
spermatogenesis	   and	   it	   is	   essential	   for	   the	   germ	   line	   integrity.	   Testicular	   cell	   adhesion	  
molecule	  1	  (TCAM1P)	  is	  a	  non-­‐coding	  transcript.	  In	  mouse,	  TCAM1	  gene	  is	  known	  to	  encode	  
a	   testis-­‐specific	   cell	   adhesion	   protein	   that	   may	   play	   a	   role	   in	   germ	   cell-­‐Sertoli	   cell	  
interactions.	   It	   regulates	   gene	  expression	   and	   it	   is	   active	   in	   stem	  cells.	  Mesoderm	   specific	  
transcript	   (MEST)	   is	   mono-­‐allelically	   expressed	   and	   epigenetically	   regulated	   non-­‐coding	  
gene.	  MEST	   function	   is	   implicated	   into	  genetic	   imprinting	  to	  regulate	  genes.	   It	   is	  known	  to	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have	  a	  role	  in	  gene	  regulation	  in	  fetal	  tissues	  and	  in	  imprinting	  in	  lymphocytes.	  The	  loss	  of	  
imprinting	  has	  been	  linked	  to	  different	  cancer	  types.	  
We	   tested	   expression	   of	   the	   selected	   genes	   by	   using	   real-­‐time	   qRT-­‐PCR	   technique	   in	   5	  
different	   cell	   lines	   that	   we	   selected	   according	   to	   their	   HPV	   status	   (positive	   or	   negative),	  
localization	  (oral	  cavity	  or	  oropharynx)	  and	  p53	  status	  (wild-­‐type	  or	  mutated).	  In	  addition	  we	  
tested	   the	   selected	   genes	   in	   2	   tumor	   samples	   selected	   according	   to	   their	   HPV	   status	  
(positive	  or	  negative).	  Another	  cell	  line,	  MDAmb231,	  was	  selected	  from	  a	  CCLE	  database	  that	  
contains	  data	  for	  gene	  expression	  across	  1000	  cell	  lines	  by	  criteria	  of	  high	  expression	  level	  of	  
SHISA2	   gene.	   MDAmb231	   is	   breast	   cancer	   cell	   line	   derived	   from	   metastatic	   site	   (pleural	  
effusion)	   and	   is	   featured	   by	   a	   mesenchymal	   phenotype	   (high	   expression	   of	   EMT-­‐related	  
proteins,	  high	  invasion	  and	  metastasis	  in	  vivo).	  MDAmb231	  was	  used	  as	  a	  positive	  control	  for	  
SHISA2	  gene	  expression	  in	  our	  experiment.	  All	  these	  samples	  are	  presented	  in	  material	  and	  
methods	  section.	  	  
The	   results	   of	   our	   experiment	   are	   presented	   in	   Figure	   6.	   The	   up-­‐regulation	   of	   SHISA2	   is	  
clearly	  shown	  in	  the	  HPV	  positive	  cell	  line	  (SCC-­‐090)	  and	  in	  the	  HPV	  positive	  clinical	  sample	  
(25).	  That	  makes	  SHISA2	  gene	  as	  a	  potential	  marker	  of	  HPV-­‐expressing	  tumors.	  SHISA2	  is	  also	  
up-­‐regulated	  as	  expected	  in	  MDAmb231	  cell	  line,	  indicating	  that	  this	  positive	  control	  works	  
well.	  	  
PARM1	  gene	  is	  up	  regulated	  in	  several	  cell	   lines	  and	  in	  the	  HPV	  negative	  clinical	  sample.	   It	  
does	  not	   seem	   to	  be	   linked	   to	  HPV	   specifically,	   and	  we	   conclude	   that	  PARM1	   gene	   is	   not	  
suitable	  as	  a	  marker	  candidate.	  
TDRD9	  gene	   is	  exclusively	  expressed	   in	  HPV	  positive	  cell	   line	  (SCC-­‐090)	  and	  not	   in	  the	  HPV	  
positive	   clinical	   sample.	   One	   explanation	   for	   this	   result	   can	   be	   the	   fact	   that	   tumor	   is	   a	  
complex	   tissue	   containing	   heterogeneous	   population	   of	   cells	   with	   different	   proliferation	  
potential.	   	   In	  contrast,	  the	  established	  cell	   lines	  are	  more	  homogeneous	  in	  respect	  to	  their	  
proliferative	   activity.	   Therefore,	   it	   is	   tempting	   to	   speculate	   that	  TDRD9	   gene	  expression	   is	  
associated	  with	  the	  proliferative	  fraction	  of	  HPV-­‐positive	  tumor	  cells.	  	  
TCAM1P	  gene	  is	  clearly	  expressed	  in	  HPV	  positive	  cell	  line	  SCC-­‐090	  and	  in	  LAU-­‐2092	  cell	  line.	  
Interestingly,	   LAU-­‐2092	   cell	   line	   is	   originating	   from	   oropharynx,	   where	   the	   most	   HPV-­‐
induced	   tumors	   originate.	   One	   explanation	   for	   this	   observation	   is	   that	   the	   expression	   of	  
some	  genes	  depends	  on	  the	  cell	  localization,	  so	  maybe	  TCAM1P	  has	  not	  the	  same	  expression	  
	   	   	   	   	   	   	  	  
	   	   	   29	  
in	   oral	   cavity	   as	   in	   oropharynx.	   Therefore,	   we	   conclude	   that	   TCAM1P	   gene	   seems	   to	   be	  
linked	  to	  oropharynx	  than	  to	  HPV.	  
MEST	  gene	   is	  up-­‐regulated	   in	  many	  cell	   lines	  without	  any	  specificity	  to	  HPV,	  therefore	   it	   is	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Figure	  6:	  qRT-­‐PCR	  analysis	  of	  gene	  expression.	  
Genes	  selected	  by	  bioinformatic	  analysis	  were	  tested	  using	  Real-­‐time	  qRT-­‐PCR	  with	  total	  RNA	  extracted	  from	  6	  head	  
and	  neck	  cancer	  cell	  lines,	  MDAmb231	  cell	  line	  and	  2	  tumor	  samples	  differing	  in	  HPV	  status.	  	  
SHISA2	   gene	   is	   clearly	   up-­‐regulated	   in	   HPV-­‐positive	   cell	   line	   and	   HPV-­‐positive	   tumor	   sample.	   PARM1	   gene	   is	   up-­‐
regulated	  in	  many	  cell	  lines	  and	  tumor	  samples.	  TDRD9	  gene	  is	  exclusively	  expressed	  in	  HPV-­‐positive	  cell	  line.	  TCAM1P	  
gene	  is	  up-­‐regulated	  in	  HPV-­‐positive	  cell	  line.	  MEST	  gene	  is	  up-­‐regulated	  in	  many	  cell	  lines.	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3.3.	  Validation	  of	  SHISA2	  protein	  expression	  by	  western	  blotting	  
According	  to	  previous	  experiments,	  we	  selected	  SHISA2	  gene	  that	  showed	  to	  be	  linked	  with	  
HPV.	  Applying	  Western	  blotting	  we	  wanted	  to	  test	  if	  SHISA2	  gene	  is	  expressed	  as	  protein	  in	  
the	   tested	   cell	   lines	   and	   tumor	   samples.	   We	   tested	   a	   commercially	   available	   SHISA2	  
antibody,	  which	   is	   distributed	  by	  multiple	   companies.	  According	   to	   the	  manufacturer,	   this	  
antibody	  has	  been	  raised	  against	  synthetic	  peptide	  between	  259-­‐288	  amino	  acids	  from	  the	  
C-­‐terminal	   region	   of	   human	   SHISA2	   protein.	   The	   theoretical	   molecular	   weight	   of	   SHISA2	  
precursor	  protein	  is	  31.4	  kDa	  (295	  aa)	  and	  molecular	  weight	  of	  SHISA2	  protein	  after	  cleavage	  
of	  the	  N-­‐terminal	  signaling	  peptide	  is	  28.3	  kDa	  (265	  aa),	  however,	  as	  shown	  in	  Figure	  7	  the	  
SHISA2	   antibody	   detects	   multiple	   proteins	   of	   higher	   molecular	   weight	   and	   no	   bands	  
correspond	  to	  the	  predicted	  protein	  size.	  This	  result	   indicates	  that	  the	  selected	  antibody	  is	  
non-­‐specific	   and	   another	   antibody	   with	   a	   validated	   specificity	   should	   be	   applied	   to	   test	  




4.	  Conclusion	  and	  discussion	  
Multiplexed	  RT-­‐PCR-­‐based	  analysis	  of	  HPV	  transcripts	  in	  tumor	  samples	  has	  shown	  that	  HPV	  
33	   expression	   in	   only	   one	   tumor	   sample.	   It	   is	   surprising	   because	   it	   is	   know	   that	   the	  
proportion	   of	   oral	   cancers	   linked	   to	   HPV	   is	   increasing,	   particularly	   in	   the	   USA.	   One	  
speculation	   for	   these	   unexpected	   results	   is	   that	   there	   are	   cultural	   differences	   between	  
Europe	   and	   USA,	   particularly	   in	   sexual	   education,	   law	   of	   health	   insurance	   and	   sexual	  
Figure	   7:	   Western	   blotting	   analysis	   of	   SHISA2	   protein	  
expression.	  	  	  
	  
(A)	  Equal	  protein	  amounts	  (15	  µg)	  of	  seven	  samples	  have	  
been	   electrophoresed	   in	   10%	   polyacrylamide	   gel	   and	  
after	  transfer	   into	  nitrocellulose	  membrane	  probed	  with	  
SHISA2	  antibody	  (PA5-­‐25853;	  1:2500).	  	  
	  
(B)	  GAPDH	  antibody	  (MAB374;	  1:5000)	  served	  as	  control	  
for	  equal	  loading.	  	  	  
	   	   	   	   	   	   	  	  
	   	   	   31	  
behaviors.	   We	   need	   also	   to	   consider	   that	   only	   four	   HPV	   isotypes	   are	   covered	   by	   our	  
multiplexed	  primers	  and	  other	  HPV	  isotypes	  related	  to	  oral	  cancer	  should	  be	  included	  in	  this	  
study.	   Alternative	   explanation	   for	   low	   frequency	   of	   the	   HPV-­‐positive	   HNSCC	   cases	   is	   the	  
nature	  of	  the	  method	  used	  to	  detect	  HPV	  in	  the	  clinical	  samples.	  Our	  method	  is	  based	  on	  the	  
detection	  of	  HPV	  transcripts,	  and	  therefore	  the	  cases	  of	  transcriptionally	  silent	  HPV	  genomes	  
integrated	   into	   the	   host	   genome	   during	   the	   initiating	   phase	   of	   HPV-­‐induced	   oral	  
tumorigenesis	  are	  not	  detected	  by	  this	  technique.	  For	  systematic	  analysis	  of	  HPV	  occurrence	  
in	  the	  clinical	  samples,	  different	  methods	  of	  HPV	  detection	  should	  be	  combined.	  Detection	  
of	  HPV	  genome	  integration	  by	  the	  diverse	  techniques	  available	  today	  (e.g.	  by	  HPV	  subtype-­‐
specific	   PCR	   from	   the	   genomic	   DNA	   or	   in	   situ	   hybridization	   on	   paraffin	   sections	   with	   the	  
specific	   probes)	   needs	   to	   be	   used	   in	   combination	  with	   our	   RNA-­‐based	   analysis	   to	   reliably	  
detect	  the	  cases	  of	  HPV-­‐induced	  and	  HPV-­‐driven	  oral	  cancer.	  	  
In	   the	   part	   of	   validation	   of	   genes	   selected	   from	  bioinformatics	   analysis,	  we	   found	   that	   at	  
least	   two	   genes	   are	   promising	   candidates	   for	   future	   work	   on	   the	   HPV-­‐induced	   HNSCC:	  
SHISA2	   and	   TDRD9.	   SHISA2	   gene	   has	   shown	   a	   good	   correlation	   with	   HPV	   and	   was	   up-­‐
regulated	  in	  HPV	  positive	  cell	  line	  and	  in	  tumor	  samples	  HPV	  positive.	  The	  fact	  that	  it	  is	  also	  
up-­‐regulated	   in	  mesenchymal	   breast	   cancer	   cell	   line	  makes	   us	   speculate	   that	   SHISA2	   has	  
probably	   a	   role	   in	   the	   regulation	   of	   epithelial-­‐mesenchymal	   transition	   (EMT).	   EMT	  means	  
that	   cells	   lose	   their	   polarity	   and	   the	   cell-­‐cell	   adhesion.	   Acquisition	   of	   mesenchymal	  
phenotype	  gives	  the	  cells	  gain	  of	  mobility	  enabling	  migration	  and	  invasion.	  This	  cell	  state	  is	  
often	  found	  in	  the	  metastatic	  cells.	  This	  could	  be	  a	  possible	  clue	  to	  target	  metastasis	  in	  HPV-­‐
positive	  HNSCC.	  
TDRD9	   gene	   is	   clearly	   expressed	   in	   HPV-­‐positive	   cell	   line	   but	   not	   in	   HPV-­‐positive	   tumor	  
sample.	   One	   explanation	   is	   that	   maybe	   TDRD9	   is	   specifically	   expressed	   by	   cycling	   tumor	  
cells,	   which	   fraction	   could	   be	   much	   higher	   in	   the	   cell	   culture	   than	   in	   the	   tumors.	  
Alternatively,	  TDRD9	  may	  be	  specifically	  expressed	  by	  cells	  expressing	  stem	  cell	  phenotype,	  
which	   frequency	   could	   be	   also	   higher	   in	   the	   cell	   culture	   than	   in	   the	   tumors.	   Other	   HPV-­‐
positive	   cell	   lines	   need	   to	   be	   tested	   for	   expression	   of	   TDRD9	   gene	   and	   potential	   role	   of	  
TDRD9	  protein	  in	  cell	  proliferation	  as	  well	  as	  for	  proposed	  function	  of	  TDRD9	  in	  the	  cancer	  
stem	  properties	  of	  HPV-­‐induced	  NHSCC.	  This	  still	  has	  to	  be	  answered	  and	  other	  studies	  are	  
needed.	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PARM1	  and	  TCAM1P	  genes	  very	  strongly	  expressed	  in	  2092	  cell	  line,	  which	  was	  derived	  from	  
oropharynx	  tumor.	  These	  genes	  don’t	  seem	  to	  be	  linked	  to	  HPV	  but	  more	  to	  the	  localization	  
of	  the	  cancer,	  which	  is	  in	  this	  case	  oropharynx.	  
At	  the	  end	  of	  this	  study,	  we	  conclude	  that	  HPV–positive	  HNSCC	  warrants	  further	  studies.	  The	  
results	  of	  our	  bioinformatic	  study	  are	  promising,	  as	  there	  are	  other	  not	  yet	  validated	  genes	  
that	   are	  putatively	   linked	   to	  HPV-­‐induced	   tumorigenesis	   and	   their	   significance	  need	   to	  be	  
tested	   in	   functional	  assays	  employing	  HPV-­‐expressing	  HNSCC	  cell	   lines.	   It	   is	   to	  expect	   that	  
further	   validation	   of	   differentially	   expressed	   genes	   will	   lead	   to	   identification	   of	   potential	  
markers	  of	  HPV-­‐associated	  oral	  cancer.	  The	  functional	  assays	  can	  potentially	  lead	  to	  design	  
of	  new	  treatment	  strategies	  of	  HPV-­‐induced	  HNSCC.	  
The	   initial	   aim	   of	   this	   master	   thesis	   was	   to	   detect	   HPV-­‐expressing	   samples,	   and	   then	   to	  
analyze	   genes	   up-­‐regulated	   in	   HPV-­‐positive	   tumors	   in	   order	   to	   better	   understand	  
mechanisms	  of	  HPV-­‐induced	  oral	  cancer.	  Our	  study	  is	  supporting	  a	  characteristic	  and	  unique	  
transcriptional	  profile	  in	  HPV-­‐induced	  HNSCC	  and	  the	  importance	  to	  consider	  and	  treat	  this	  
disease	   as	   an	   independent	   cancer	   entity.	   Further	   studies	   need	   to	   be	   performed	   to	   better	  
understand	   HPV-­‐induced	   carcinogenesis	   and	   clinical	   behavior	   of	   HPV-­‐positive	   cancers	   in	  
order	   to	   improve	   disease	   prevention,	   patient	   care,	   and	   to	   develop	   new	   therapeutic	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